

Stanford



Ronald Levy, MD

Robert K. and Helen K. Summy Professor in the School of Medicine
Medicine - Oncology

 NIH Biosketch available Online

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Lymphoma Clinic**

875 Blake Wilbur Dr Clinic C

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 725-9113

Bio

CLINICAL FOCUS

- Cancer > Lymphoma
- Lymphoma
- Non-Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma - Medical Oncology
- Burkitt's Lymphoma
- Burkitt's Lymphoma - Medical Oncology
- Hodgkin's Disease
- Hodgkin's Disease - Medical Oncology
- Burkitt's Lymphoma - Hematology
- Hodgkin's Disease - Hematology
- Oncology (Cancer)
- Non-Hodgkin's Lymphoma - Hematology
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Karnofsky Award, American Society of Clinical Oncology (1999)
- Charles Kettering Prize, General Motors Cancer Research Foundation (1999)
- C.Chester Stock Award, Memorial Sloan-Kettering Cancer Center (2000)

- Medal of Honor, American Cancer Society (2000)
- Jeffrey A. Gottlieb Memorial Award, M.D. Anderson Cancer Center (2003)
- Damashek Prize, American Society of Hematology (2004)
- Member, Institute of Medicine (2007)
- di Villiers International Achievement Award, Leukemia and Lymphoma Society (2007)
- Member, National Academy of Sciences (2008)
- King Faisal International Prize, King Faisal Foundation (2009)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University School of Medicine (1973) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (1979)
- Residency: Massachusetts General Hospital (1970) MA
- Internship: Massachusetts General Hospital (1969) MA
- Board Certification: Internal Medicine, American Board of Internal Medicine (1973)
- Medical Education: Stanford University School of Medicine (1968) CA
- AB, Harvard University , Biochemistry (1963)
- MD, Stanford University , Medicine (1968)

LINKS

- http://med.stanford.edu/labs/ronald_levy/
- Personal Web site: http://med.stanford.edu/labs/ronald_levy/
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Our research concentrates on the study of malignant lymphoma and tumors of the immune system using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Receptor molecules present on the surface of tumor cells transmit signals for regulation of cell growth. These receptors include the immunoglobulin molecule on B cell tumors and the T cell receptor on T cell tumors. Questions the lab is currently addressing include:

1. Can a clue to the pathogenesis of lymphoma be derived from a study of their antigen receptors?
2. Can new treatments for lymphoma be developed by targeting receptors with monoclonal antibodies?
3. Can vaccines be developed which can induce an immune response in the host against the receptors on their own tumor?

CLINICAL TRIALS

- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease, Recruiting
- A Phase I/II Study of Intratumoral Injection of SD-101, Not Recruiting
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment, Not Recruiting
- CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas, Not Recruiting
- Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP), Not Recruiting
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma, Not Recruiting
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas, Not Recruiting

- TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma, Not Recruiting

Teaching

STANFORD ADVISEES

Med Scholar Project Advisor

Jigyasa Sharma

Doctoral Dissertation Reader (AC)

Markus Diehl, Vishnu Shankar

Postdoctoral Faculty Sponsor

Ha Rin Kim

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Immunology (Phd Program)

Publications

PUBLICATIONS

- **Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma**

Kirane, A., Lee, D., Ahmad, M., Sharma, S., Serasanambati, M., Lowe, M., Applebee, C., Safrygina, E., Swetter, S., Reddy, S., Warner, A., Funchain, P., Wang, et al
SPRINGER.2024: S33-S34

- **A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.** *Blood advances*

Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L., Alizadeh, A. A., Advani, R. H., Hoppe, R. T., Long, et al
2023

- **Co-Occurrence of Clonally Related Follicular Lymphoma and Histiocytic Sarcoma**

Haebe, S., Czerwinski, D. K., Sathe, A., Grimes, S., Chen, T., Martin, B., Ji, H., Levy, R., Shree, T.
AMER SOC HEMATOLOGY.2023

- **Loss of the OX40 Target in Lymphoma Patients after Combining an Anti-OX40 Agonist Antibody with in Situ Vaccination**

Czerwinski, D. K., Shree, T., Haebe, S., Shi, S., Long, S. R., Martin, B., Levy, R.
AMER SOC HEMATOLOGY.2023

- **Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.** *Blood*

Haebe, S. E., Day, G., Czerwinski, D. K., Sathe, A., Grimes, S. M., Chen, T., Long, S. R., Martin, B. A., Ozawa, M. G., Ji, H. P., Shree, T., Levy, R.
2023

- **Single-cell multi-gene identification of somatic mutations and gene rearrangements in cancer.** *Nature cancer*

Grimes, S. M., Kim, H. S., Roy, S., Sathe, A., Ayala, C. I., Bai, X., Almeda-Notestine, A. F., Haebe, S., Shree, T., Levy, R., Lau, B. T., Ji, H. P.
2023; 5 (3): zcad034

- **The molecular mechanism of CD81 antibody inhibition of metastasis.** *Proceedings of the National Academy of Sciences of the United States of America*

Abu-Saleh, N., Kuo, C. C., Jiang, W., Levy, R., Levy, S.
2023; 120 (26): e2305042120

- **Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors.** *Journal of immunology (Baltimore, Md. : 1950)*

Miller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Bertozzi, C. R., Cochran, J. R., Levy, R.

2023

- **Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs.** *Bioconjugate chemistry*
Blake, T. R., Haabeth, O. A., Sallets, A., McClellan, R. L., Del Castillo, T. J., Vilches-Moure, J. G., Ho, W. C., Wender, P. A., Levy, R., Waymouth, R. M.
2023
- **Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program** *JOURNAL OF CLINICAL ONCOLOGY*
McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczmar, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, et al
2023; 41 (2): 154-162
- **Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma**
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L. S., Alizadeh, A. A., Advani, R. H., Hoppe, R., Long, et al
AMER SOC HEMATOLOGY.2022: 6450-6451
- **Prevalence of Acquired N-Glycosylation Sites at the Single Cell Level in Follicular Lymphoma**
Haebe, S., Shree, T., Day, G., Czerwinski, D. K., Sathe, A., Grimes, S. M., Long, S. R., Martin, B., Ozawa, M. G., Ji, H. P., Levy, R.
AMER SOC HEMATOLOGY.2022: 9211-9212
- **PROFILING THE EFFECTS OF TARGETED TLR9 STIMULATION WITHIN SPONTANEOUSLY ARISING BREAST TUMORS**
Miller, C., Sagiv-Barfi, I., Neuhofer, P., Czerwinski, D., Bertoza, C., Cochran, J., Levy, R.
BMJ PUBLISHING GROUP.2022: A1209
- **PARP14 is a novel target in STAT6 mutant follicular lymphoma.** *Leukemia*
Mentz, M., Keay, W., Strobl, C. D., Antonioli, M., Adolph, L., Heide, M., Lechner, A., Haebe, S., Osterode, E., Kridel, R., Ziegenhain, C., Wange, L. E., Hildebrand, et al
2022
- **Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro.** *Biomacromolecules*
Testa, S., Haabeth, O. A., Blake, T. R., Del Castillo, T. J., Czerwinski, D. K., Rajapaksa, R., Wender, P. A., Waymouth, R. M., Levy, R.
2022
- **Intratumoral immunotherapy relies on B and T cell collaboration.** *Science immunology*
Sagiv-Barfi, I., Czerwinski, D. K., Shree, T., Lohmeyer, J. J., Levy, R.
2022; 7 (71): eabn5859
- **Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.** *Cancer research*
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., Levy, R.
2022
- **CD81 costimulation skews CAR transduction toward naive T cells.** *Proceedings of the National Academy of Sciences of the United States of America*
Schultz, L. M., Czerwinski, D. K., Levy, R., Levy, S.
1800; 119 (5)
- **CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.** *Blood cancer discovery*
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbelli, K. S., Gabriel, E., Kurtz, D. M., Khodadoust, M. S., Gupta, et al
2022
- **Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma**
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., Advani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Kurtz, D. M., Corbelli, K. S., Gabriel, et al
AMER SOC HEMATOLOGY.2021
- **In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity**
Barfi, I., Czerwinski, D. K., Levy, R.
AMER SOC HEMATOLOGY.2021

- **Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation**
Shree, T., Haebe, S., Czerwinski, D. K., Day, G., Sathe, A., Khodadoust, M. S., Frank, M. J., Beygi, S., Hoppe, R., Long, S. R., Martin, B., Ji, H. P., Levy, et al
AMER SOC HEMATOLOGY.2021
- **In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions**
Haebe, S., Shree, T., Day, G., Sathe, A., Czerwinski, D. K., Grimes, S. M., Long, S. R., Martin, B., Hoppe, R., Ji, H. P., Levy, R.
AMER SOC HEMATOLOGY.2021
- **SYSTEMIC DELIVERY OF A TUMOR-TARGETED TLR9 AGONIST CONJUGATE TRANSFORMS THE TUMOR IMMUNE LANDSCAPE AND INDUCES TUMOR REGRESSION IN MICE**
Candidate, C., Sagiv-Barfi, I., Neuhofer, P., Czerwinski, D., Artandi, S., Bertozzi, C., Levy, R., Cochran, J.
BMJ PUBLISHING GROUP.2021: A803
- **An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.** *ACS central science*
Haabeth, O. A., Lohmeyer, J. J., Sallets, A., Blake, T. R., Sagiv-Barfi, I., Czerwinski, D. K., McCarthy, B., Powell, A. E., Wender, P. A., Waymouth, R. M., Levy, R.
2021; 7 (7): 1191-1204
- **Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma.** *Blood*
Haebe, S. E., Shree, T. n., Sathe, A. n., Day, G. n., Czerwinski, D. K., Grimes, S. n., Lee, H. n., Binkley, M. S., Long, S. R., Martin, B. A., Ji, H. P., Levy, R. n.
2021
- **How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.** *Blood cancer discovery*
Ribas, A., Dhodapkar, M. V., Campbell, K. M., Davies, F. E., Gore, S. D., Levy, R., Greenberger, L. M.
2021; 2 (6): 562-567
- **Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.** *Cell chemical biology*
Miller, C. L., Sagiv-Barfi, I., Neuhofer, P., Czerwinski, D. K., Artandi, S. E., Bertozzi, C. R., Levy, R., Cochran, J. R.
2021
- **Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy.** *Cancer cytopathology*
Mooney, K. L., Czerwinski, D. K., Shree, T., Frank, M. J., Haebe, S., Martin, B. A., Testa, S., Levy, R., Long, S. R.
2021
- **Targeting the tetraspanin CD81 reduces cancer invasion and metastasis.** *Proceedings of the National Academy of Sciences of the United States of America*
Vences-Catalán, F., Rajapaksa, R., Kuo, C. C., Miller, C. L., Lee, A., Ramani, V. C., Jeffrey, S. S., Levy, R., Levy, S.
2021; 118 (24)
- **Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.** *Journal for immunotherapy of cancer*
Neelapu, S. S., Adkins, S., Ansell, S. M., Brody, J., Cairo, M. S., Friedberg, J. W., Kline, J. P., Levy, R., Porter, D. L., van Besien, K., Werner, M., Bishop, M. R.
2020; 8 (2)
- **Neoadjuvant Immunotherapy for Solid Tumors**
Hong, W., Sagiv-Barfi, I., Czerwinski, D., Levy, R.
ELSEVIER SCIENCE INC.2020: S275
- **Neoadjuvant immunotherapy for solid tumors**
Hong, W., Sagiv-Barfi, I., Czerwinski, D., Levy, R.
AMER ASSOC CANCER RESEARCH.2020
- **Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Shree, T., Li, Q., Glaser, S. L., Brunson, A., Maecker, H. T., Haile, R. W., Levy, R., Keegan, T. H.
2020: JCO1901937
- **Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.** *American journal of hematology*
Timmerman, J., Herbaux, C., Ribrag, V., Zelenetz, A. D., Houot, R., Neelapu, S. S., Logan, T., Lossos, I. S., Urba, W., Salles, G., Ramchandren, R., Jacobson, C., Godwin, et al

2020

- Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? *European journal of cancer (Oxford, England : 1990)*
Houot, R. n., Levy, R. n., Cartron, G. n., Armand, P. n.
2020; 136: 4–6
- First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*
Gopal, A. K., Levy, R. n., Houot, R. n., Patel, S. P., Popplewell, L. n., Jacobson, C. n., Mu, X. J., Deng, S. n., Ching, K. A., Chen, Y. n., Davis, C. B., Huang, B. n., Fly, et al
2020
- Intratumoral immunotherapy for early stage solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*
Hong, W. X., Haebe, S. n., Lee, A. n., Westphalen, B. n., Norton, J. A., Jiang, W. n., Levy, R. n.
2020
- Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. *Blood advances*
Wilk, A. J., Weidenbacher, N. L., Vergara, R. n., Haabeth, O. A., Levy, R. n., Waymouth, R. M., Wender, P. A., Blish, C. A.
2020; 4 (17): 4244–55
- Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoing in situ vaccination
Shree, T., Sathe, A., Ji, H., Levy, R.
AMER ASSOC CANCER RESEARCH.2019
- Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma
Shree, T., Khodadoust, M. S., Czerwinski, D., Frank, M. J., Hong, W. X., Greenstein, R., Guo, S., Long, S., Martin, B. A., Levy, R.
AMER ASSOC CANCER RESEARCH.2019
- CD81 is a novel immunotherapeutic target for B cell lymphoma. *The Journal of experimental medicine*
Vences-Catalan, F., Kuo, C., Rajapaksa, R., Duault, C., Andor, N., Czerwinski, D. K., Levy, R., Levy, S.
2019
- Local Delivery of Ox40L, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity *CANCER RESEARCH*
Haabeth, O., Blake, T. R., McKinlay, C. J., Tveita, A. A., Sallets, A., Waymouth, R. M., Wender, P. A., Levy, R.
2019; 79 (7): 1624–34
- Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints *BLOOD*
Andor, N., Simonds, E. F., Czerwinski, D. K., Chen, J., Grimes, S. M., Wood-Bouwens, C., Zheng, G. Y., Kubit, M. A., Greer, S., Weiss, W. A., Levy, R., Ji, H. P.
2019; 133 (10): 1119–29
- Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy
Mooney, K., Long, S., Martin, B., Frank, M., Czerwinski, D., Levy, R., Guo, X., Shree, T., Greenstein, R.
NATURE PUBLISHING GROUP.2019
- Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy
Mooney, K., Long, S., Martin, B., Frank, M., Czerwinski, D., Levy, R., Guo, X., Shree, T., Greenstein, R.
NATURE PUBLISHING GROUP.2019
- Local delivery of OX40L, CD80, and CD86 mRNA kindles global anti-cancer immunity. *Cancer research*
Haabeth, O. A., Blake, T. R., McKinlay, C. J., Tveita, A. A., Sallets, A., Waymouth, R. M., Wender, P. A., Levy, R.
2019
- TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma. *Cancer immunology research*

Josefsson, S. E., Beiske, K., Blaker, Y. N., Forsund, M. S., Holte, H., Ostenstad, B., Kimby, E., Koksal, H., Walchli, S., Bai, B., Smeland, E. B., Levy, R., Kolstad, et al
2019

● **Predicting HLA class II antigen presentation through integrated deep learning.** *Nature biotechnology*

Chen, B. n., Khodadoust, M. S., Olsson, N. n., Wagar, L. E., Fast, E. n., Liu, C. L., Muftuoglu, Y. n., Sworder, B. J., Diehn, M. n., Levy, R. n., Davis, M. M., Elias, J. E., Altman, et al
2019

● **Single-cell RNA-Seq of lymphoma cancers reveals malignant B cell types and co-expression of T cell immune checkpoints.** *Blood*

Andor, N., Simonds, E. F., Czerwinski, D. K., Chen, J., Grimes, S. M., Wood-Bouwens, C., Zheng, G. X., Kubit, M. A., Greer, S., Weiss, W. A., Levy, R., Ji, H. P.
2018

● **Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an In Situ Vaccination Clinical Trial**

Shree, T., Sathe, A., Czerwinski, D. K., Long, S. R., Ji, H., Levy, R.
AMER SOC HEMATOLOGY.2018

● **Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.** *Blood advances*

Sallets, A., Robinson, S., Kardosh, A., Levy, R.
2018; 2 (17): 2230–41

● **mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.** *Proceedings of the National Academy of Sciences of the United States of America*

Haabeth, O. A., Blake, T. R., McKinlay, C. J., Waymouth, R. M., Wender, P. A., Levy, R.
2018

● **Circulating tumor DNA (ctDNA) in B-cell lymphoma**

Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al
WILEY.2018: 16–17

● **In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.** *Cancer discovery*

Frank, M. J., Reagan, P. M., Bartlett, N. L., Gordon, L. I., Friedberg, J. W., Czerwinski, D. K., Long, S. R., Hoppe, R. T., Janssen, R. S., Candia, A. F., Coffman, R. L., Levy, R.
2018

● **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018: JCO2018785246

● **Positron emission tomography imaging of activated T cells by targeting OX40 reveals spatiotemporal immune dynamics and predicts response to in situ tumor vaccination**

Mayer, A. T., Alam, I. S., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., Johnson, E. M., James, M. L., Levy, R., Gambhir, S. S.
AMER ASSOC CANCER RESEARCH.2018

● **Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer** *CLINICAL CANCER RESEARCH*

Segal, N. H., He, A. R., Doi, T., Levy, R., Bhatia, S., Pishvaian, M. J., Cesari, R., Chen, Y., Davis, C. B., Huang, B., Thall, A. D., Gopal, A. K.
2018; 24 (8): 1816–23

● **T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling** *CLINICAL CANCER RESEARCH*

Josefsson, S. E., Huse, K., Kolstad, A., Beiske, K., Pende, D., Steen, C. B., Inderberg, E., Lingjaerde, O., Ostenstad, B., Smeland, E. B., Levy, R., Irish, J. M., Myklebust, et al
2018; 24 (4): 870–81

● **Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.** *Scientific reports*

Turaj, A. H., Cox, K. L., Penfold, C. A., French, R. R., Mockridge, C. I., Willoughby, J. E., Tutt, A. L., Griffiths, J., Johnson, P. W., Glennie, M. J., Levy, R., Cragg, M. S., Lim, et al
2018; 8 (1): 2278

- **Eradication of spontaneous malignancy by local immunotherapy.** *Science translational medicine*
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., Levy, R.
2018; 10 (426)
- **Eradication of spontaneous malignancy by local immunotherapy.** *SCIENCE TRANSLATIONAL MEDICINE*
Sagiv-Barfi, I., Czerwinski, D., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., Levy, R.
2018; 10 (426)
- **B cell lymphomas present immunoglobulin neoantigens.** *Blood*
Khodadoust, M. S., Olsson, N. n., Chen, B. n., Sworder, B. n., Shree, T. n., Liu, C. L., Zhang, L. n., Czerwinski, D. K., Davis, M. M., Levy, R. n., Elias, J. E., Alizadeh, A. A.
2018
- **Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.** *Cell stem cell*
Kooreman, N. G., Kim, Y. n., de Almeida, P. E., Termglinchan, V. n., Diecke, S. n., Shao, N. Y., Wei, T. T., Yi, H. n., Dey, D. n., Nelakanti, R. n., Brouwer, T. P., Paik, D. T., Sagiv-Barfi, et al
2018
- **Imaging activated T cells predicts response to cancer vaccines.** *The Journal of clinical investigation*
Alam, I. S., Mayer, A. T., Sagiv-Barfi, I. n., Wang, K. n., Vermesh, O. n., Czerwinski, D. K., Johnson, E. M., James, M. L., Levy, R. n., Gambhir, S. S.
2018
- **T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins.** *Proteomics*
Olsson, N. n., Schultz, L. M., Zhang, L. n., Khodadoust, M. S., Narayan, R. n., Czerwinski, D. K., Levy, R. n., Elias, J. E.
2018
- **Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, et al
2017; 377 (26): 2531–44
- **Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody** *CLINICAL CANCER RESEARCH*
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, et al
2017; 23 (8): 1929-1936
- **CD81 as a tumor target.** *Biochemical Society transactions*
Vences-Catalán, F., Duault, C., Kuo, C., Rajapaksa, R., Levy, R., Levy, S.
2017; 45 (2): 531-535
- **Epstein-Barr virus-positive follicular lymphoma** *MODERN PATHOLOGY*
Mackrides, N., Campuzano-Zuluaga, G., Maque-Acosta, Y., Moul, A., Hijazi, N., Ikpatt, F. O., Levy, R., Verdun, R. E., Kunkalla, K., Natkunam, Y., Lossos, I. S., Vega, F., Chapman, et al
2017; 30 (4): 519-529
- **Epstein-Barr virus-positive follicular lymphoma.** *Modern pathology*
Mackrides, N., Campuzano-Zuluaga, G., Maque-Acosta, Y., Moul, A., Hijazi, N., Ikpatt, F. O., Levy, R., Verdun, R. E., Kunkalla, K., Natkunam, Y., Lossos, I. S., Vega, F., Chapman, et al
2017; 30 (4): 519-529
- **Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens** *NATURE*
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A., Chen, B., Swaminathan, K., Rawson, K., Liu, C. L., Steiner, D., Lund, P., Rao, S., Zhang, L., Marceau, et al
2017; 543 (7647): 723-?
- **Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.** *Blood*
Myklebust, J. H., Brody, J., Kohrt, H. E., Kolstad, A., Czerwinski, D. K., Wälchli, S., Green, M. R., Trøen, G., Liestøl, K., Beiske, K., Houot, R., Delabie, J., Alizadeh, et al
2017; 129 (6): 759-770

- **The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*
Boyiadzis, M., Bishop, M. R., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A., Van Besien, K., Bergsagel, P., Borrello, I., Brody, J., Brufsky, et al
2016; 4: 90
- **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al
2016; 8 (364)
- **Results From an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.** *Clinical cancer research*
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D. F., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiariom-Silene, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, et al
2016
- **Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Torchia, J., Weiskopf, K., Levy, R.
2016; 113 (19): 5376-5381
- **Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop** *ONCOIMMUNOLOGY*
Houot, R., Gaulard, P., Schreiber, R., Mellman, I., Lambotte, O., Coulie, P. G., Fest, T., Korman, A., Levy, R., Shipp, M., Tarte, K., Kohrt, H., Marabelle, et al
2016; 5 (7)
- **Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis** *ONCOIMMUNOLOGY*
Vences-Catalan, F., Rajapaksa, R., Srivastava, M. K., Marabelle, A., Kuo, C., Levy, R., Levy, S.
2016; 5 (5): e1120399
- **Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses**
Sagiv-Barfi, I., Lu, H., Hewitt, J., Hsu, F. J., ter Meulen, J., Levy, R.
AMER SOC HEMATOLOGY.2015
- **Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy**
Chan, W., Theriault, T., Levy, R., Swartz, J.
AMER SOC HEMATOLOGY.2015
- **T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC**
Schultz, L. M., Olsson, N., Khodadoust, M., Narayan, R., Sagiv-Barfi, I., Elias, J., Levy, R.
AMER SOC HEMATOLOGY.2015
- **Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN**
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Chu, M. P., Okada, A., McDonald, K. A., Kohrt, H. E., Bartlett, N. L., Reagan, P. M., Friedberg, J. W., Gordon, L. I., Coffman, et al
AMER SOC HEMATOLOGY.2015
- **Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma**
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Craig, A. M., Chabon, J. J., Lovejoy, A. F., Klass, D. M., Glover, C., Ohgami, R. S., Kunder, et al
AMER SOC HEMATOLOGY.2015
- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
AMER SOC HEMATOLOGY.2015
- **Tetraspanin CD81 Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory and Myeloid-Derived Suppressor Cells** *CANCER RESEARCH*
Vences-Catalan, F., Rajapaksa, R., Srivastava, M. K., Marabelle, A., Kuo, C., Levy, R., Levy, S.
2015; 75 (21): 4517-4526

- **Monoclonal antibodies and in situ vaccination.**

Levy, R.

AMER ASSOC CANCER RESEARCH.2015

- **Combining Ibrutinib with immune checkpoint blockade to induce therapeutic antitumor immune response in solid tumors**

Sagiv-Barfi, I., Kohrt, H., Czerwinski, D., Ng, P., Chang, B., Levy, R.

AMER ASSOC CANCER RESEARCH.2015

- **Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. *Blood***

Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., Visser, B., Callahan, J., Kong, et al

2015; 125 (24): 3679-3687

- **Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)**

Scherer, F., Kurtz, D., Green, M., Newman, A. M., Klass, D. M., Zhou, L., Krishnan, R., Liu, C., Glover, C., Ohgami, R. S., Hicks, R. J., Keane, C., Kong, et al
AMER SOC CLINICAL ONCOLOGY.2015

- **First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.**

Brownstein, C. M., Adriaens, L., Bannerji, R., Chavez, J. C., Levy, R., Ansell, S., Advani, R. H., Patel, S., Kostic, A., Trail, P., Lowy, I., Kohrt, H.
AMER SOC CLINICAL ONCOLOGY.2015

- **Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.**

Kurtz, D., Scherer, F., Green, M., Khodadoust, M., Klass, D. M., Zhou, L., Krishnan, R., Glover, C., Liu, C., Kong, K. A., Faham, M., Levy, R., Diehn, et al
AMER SOC CLINICAL ONCOLOGY.2015

- **Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillimumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.**

Khodadoust, M., Chu, M., Czerwinski, D., McDonald, K., Long, S., Kohrt, H., Hoppe, R. T., Advani, R. H., Lowsky, R., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2015

- **A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+NHL.**

Gopal, A. K., Bartlett, N. L., Levy, R., Houot, R., Smith, S., Segal, N., Thall, A. D., Mugundu, G., Huang, B., Davis, C., Kohrt, H.
AMER SOC CLINICAL ONCOLOGY.2015

- **Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. *Blood***

Sagiv-Barfi, I., Kohrt, H. E., Burckhardt, L., Czerwinski, D. K., Levy, R.

2015; 125 (13): 2079-2086

- **A roadmap for discovery and translation in lymphoma *BLOOD***

Weinstock, D. M., Dalla-Favera, R., Gascoyne, R. D., Leonard, J. P., Levy, R., Lossos, I. S., Melnick, A. M., Nowakowski, G. S., Press, O. W., Savage, K. J., Shipp, M. A., Staudt, L. M.
2015; 125 (13): 2175-77

- **Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. *Proceedings of the National Academy of Sciences of the United States of America***

Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., Irish, J., Stehr, H., Vicente-Dueñas, C., Romero-Camarero, I., Sanchez-Garcia, I., Plevritis, S. K., Arber, et al
2015; 112 (10): E1116-25

- **Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. *Proceedings of the National Academy of Sciences of the United States of America***

Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., Irish, J., Stehr, H., Vicente-Dueñas, C., Romero-Camarero, I., Sanchez-Garcia, I., Plevritis, S. K., Arber, et al
2015; 112 (10): E1116-25

- **Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. *Proceedings of the National Academy of Sciences of the United States of America***

Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y., Levy, R.
2015; 112 (9): E966-72

- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. *Proceedings of the National Academy of Sciences of the United States of America*
Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y., Levy, R.
2015; 112 (9): E966-72
- CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma *CLINICAL CANCER RESEARCH*
Knox, S. J., Levy, R.
2015; 21 (3): 493-94
- Current Clinical Trials Testing Combinations of Immunotherapy and Radiation *SEMINARS IN RADIATION ONCOLOGY*
Crittenden, M., Kohrt, H., Levy, R., Jones, J., Camphausen, K., Dicker, A., Demaria, S., Formenti, S.
2015; 25 (1): 54-64
- Generating Chimeric Antigen Receptors Utilizing Novel Anti-CD3 Nanobeads
Schultz, L. M., Czerwinski, D. K., Fu, A., Levy, S., Levy, R.
AMER SOC HEMATOLOGY.2014
- Local tumor irradiation combined with alpha-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series
Sagiv-Barfi, I., Rajapaksa, A., Czerwinski, D., Chang, S., Hebb, J., Chester, C., Waller, E., Fine, G., Chen, D., Kowanetz, M., Irving, B., Levy, R., Kohrt, et al
AMER ASSOC CANCER RESEARCH.2014
- Semi-synthetic peptibodies are a novel personalized therapeutic with activity against lymphoma in vitro and in vivo
Torchia, J., Ng, P., Chen, H., Weiskopf, K., Levy, R.
AMER ASSOC CANCER RESEARCH.2014
- Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. *Journal of immunology*
Lim, S. H., Levy, R.
2014; 193 (4): 1519-1524
- New insights into the mechanism of action of immune checkpoint antibodies. *Oncotarget*
Marabelle, A., Kohrt, H., Levy, R.
2014; 3 (8): e954869
- New insights into the mechanism of action of immune checkpoint antibodies *ONCOIMMUNOLOGY*
Marabelle, A., Kohrt, H., Levy, R.
2014; 3 (8)
- Joint Modeling and Registration of Cell Populations in Cohorts of High-Dimensional Flow Cytometric Data *PLOS ONE*
Pyne, S., Lee, S. X., Wang, K., Irish, J., Tamayo, P., Nazaire, M., Duong, T., Shu-Kay Ng, S. K., Hafler, D., Levy, R., Nolan, G. P., Mesirov, J., McLachlan, et al
2014; 9 (7)
- Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. *Journal of clinical oncology*
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al
2014; 32 (17): 1797-1803
- Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. *Journal of clinical oncology*
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al
2014; 32 (17): 1797-1803
- Targeting CD137 enhances the efficacy of cetuximab. *Journal of clinical investigation*
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, et al
2014; 124 (6): 2668-2682
- Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
Chester, C., Chang, S., Kurland, J. F., Sagiv-Barfi, I., Czerwinski, D., Rajapaksa, A., Waller, E., Sadaram, M., Richards, L., Cohen, L. J., Ahlers, C., Jure-Kunkei, M., Maecker, et al

AMER SOC CLINICAL ONCOLOGY.2014

● **A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.**

Segal, N., Gopal, A. K., Bhatia, S., Kohrt, H., Levy, R., Pishvalan, M. J., Houot, R., Bartlett, N., Nghlem, P., Kronenberg, S., Thali, A. D., Mugundu, G., Huang, et al

AMER SOC CLINICAL ONCOLOGY.2014

● **Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.**

Kurtz, D., Green, M. R., Bratman, S., Liu, C., Glover, C., Keane, C., Kong, K., Faham, M., Miklos, D., Advani, R. H., Levy, R., Hertzberg, M. S., Gandhi, et al

AMER SOC CLINICAL ONCOLOGY.2014

● **A brief personal history of cancer immunotherapy at Stanford: if these walls could talk.... *Immunologic research***

Levy, R.

2014; 58 (2-3): 277-281

● **Intratumoral immunization: a new paradigm for cancer therapy. *Clinical cancer research***

Marabelle, A., Kohrt, H., Caux, C., Levy, R.

2014; 20 (7): 1747-1756

● **Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. *Blood***

Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E., Butchar, J. P., Cheney, C., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., Johnson, A. J., Byrd, J. C. 2014; 123 (12): 1957-1960

● **B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. *Blood***

Ng, P. P., Kuo, C., Wang, S., Einav, S., Arcaini, L., Paulli, M., Portlock, C. S., Marcotrigiano, J., Tarr, A., Ball, J., Levy, R., Levy, S.

2014; 123 (10): 1512-1515

● **Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. *Blood***

Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., Waller, E., Ugolini, S., Vivier, et al

2014; 123 (5): 678-686

● **Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity *CLINICAL CANCER RESEARCH***

Marabelle, A., Kohrt, H., Levy, R.

2013; 19 (19): 5261-5263

● **Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013) *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION***

Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J. 2013; 19 (10): 1530

● **Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. *Clinical cancer research***

Marabelle, A., Kohrt, H., Levy, R.

2013; 19 (19): 5261-5263

● **Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. *Blood***

Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., Warnke, R. A., Natkunam, Y., Han, S. S., Yuen, A., Plevritis, S. K., Advani, R. H. 2013; 122 (6): 981-987

● **Enhancement of antibody fragment secretion into the Escherichia coli periplasm by co-expression with the peptidyl prolyl isomerase, FkpA, in the cytoplasm *JOURNAL OF IMMUNOLOGICAL METHODS***

Levy, R., Ahluwalia, K., Bohmann, D. J., Giang, H. M., Schwimmer, L. J., Issafras, H., Reddy, N. B., Chan, C., Horwitz, A. H., Takeuchi, T. 2013; 394 (1-2): 10-21

● **Depleting tumor-specific Tregs at a single site eradicates disseminated tumors *JOURNAL OF CLINICAL INVESTIGATION***

Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., Luong, R., Rosenblum, M. D., Steinman, et al

2013; 123 (6): 2447-2463

● **Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity.**

Kohrt, H., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Lira, R. R., Troutner, E., Richards, L., Rajapaksa, A., Ostashko, A., Weng, W., Chen, L., Colevas, et al

AMER SOC CLINICAL ONCOLOGY.2013

- **An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.**
Salles, G. A., Gopal, A. K., Martin, P., Marcus, R., Hess, G., Zinzani, P., Ahmadi, T., Zhuang, S., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2013
- **A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies**
Kohrt, H., Godwin, J. E., Lossos, I. S., Williams, M. E., Timmerman, J., Link, B. K., Goldberg, S. M., McGirr, A., Kurland, J. F., Wigginton, J. M., Cohen, L. J., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2013
- **A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL)**
Melerio, I., Gangadhar, T. C., Kohrt, H., Segal, N., Logan, T., Urba, W., Hodi, F., Ott, P., Perez-Gracia, J., Wolchok, J. D., Shah, A., Kurland, J. F., Cohen, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.** *Blood*
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., Kela, I., Hopmans, E. S., Myklebust, J. H., Ji, H., Plevritis, S. K., Levy, R., Alizadeh, et al
2013; 121 (9): 1604-1611
- **High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.** *Blood*
Myklebust, J. H., Irish, J. M., Brody, J., Czerwinski, D. K., Houot, R., Kohrt, H. E., Timmerman, J., Said, J., Green, M. R., Delabie, J., Kolstad, A., Alizadeh, A. A., Levy, et al
2013; 121 (8): 1367-1376
- **Cancer Vaccines and T Cell Therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J.
2013; 19 (1): S97-S101
- **Local immunomodulation at a single site of tumor generates a therapeutic immune response that cures metastatic disease at distant sites, including the brain.**
Marabelle, A., Kohrt, H., Levy, R.
AMER ASSOC CANCER RESEARCH.2013
- **in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Czerwinski, D. K., Brody, J., Kohrt, H. E., Hoppe, R. T., Advani, R. H., Levy, R.
AMER SOC HEMATOLOGY.2012
- **Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Torchia, J. A., Ng, P. P., Chen, H., Kohrt, H. E., Marabelle, A., Alizadeh, A. A., Levy, R.
AMER SOC HEMATOLOGY.2012
- **Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Levy, R., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2012
- **Self-antigen recognition by follicular lymphoma B-cell receptors** *BLOOD*
Sachen, K. L., Strohman, M. J., Singletary, J., Alizadeh, A. A., Kattah, N. H., Lossos, C., Mellins, E. D., Levy, S., Levy, R.
2012; 120 (20): 4182-4190
- **A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Ng, P. P., Jia, M., Patel, K. G., Brody, J. D., Swartz, J. R., Levy, S., Levy, R.
2012; 109 (36): 14526-14531
- **CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas Diagnostic and Therapeutic Implications** *AMERICAN JOURNAL OF PATHOLOGY*

- Anderson, M. W., Zhao, S., Freud, A. G., Czerwinski, D. K., Kohrt, H., Alizadeh, A. A., Houot, R., Azambuja, D., Biasoli, I., Morais, J. C., Spector, N., Molina-Kirsch, H. F., Warnke, et al
2012; 181 (3): 795-803
- **Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody** *ONCOIMMUNOLOGY*
Houot, R., Kohrt, H., Levy, R.
2012; 1 (6): 957-958
 - **Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., Sunwoo, J., Tedder, et al
AMER SOC CLINICAL ONCOLOGY.2012
 - **Combination strategies to enhance antitumor ADCC** *IMMUNOTHERAPY*
Kohrt, H. E., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M., Levy, R., Brody, J.
2012; 4 (5): 511-527
 - **In situ Treg immunomodulation at a single tumor site with CpG and immune checkpoint antibodies cures metastatic disease**
Marabelle, A., Kohrt, H., Brody, J., Torchia, J., Rajapaksa, R., Luong, R., Zhou, G., Levitsky, H., Tse, V., Levy, R.
AMER ASSOC CANCER RESEARCH.2012
 - **Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells** *CANCER RESEARCH*
Goldstein, M. J., Kohrt, H. E., Houot, R., Varghese, B., Lin, J. T., Swanson, E., Levy, R.
2012; 72 (5): 1239-1247
 - **Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer** *JOURNAL OF CLINICAL INVESTIGATION*
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., Stockdale, F. E., Mollick, J. A., Chen, et al
2012; 122 (3): 1066-1075
 - **Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Sagi, Y., Landrigan, A., Levy, R., Levy, S.
2012; 109 (5): 1613-1618
 - **Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., Faham, M., Advani, R., Kohrt, H. E., Alizadeh, A. A., Negrin, R. S., Weng, W., Sheehan, et al
AMER SOC HEMATOLOGY.2011: 1323-23
 - **Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy** *TRENDS IN IMMUNOLOGY*
Houot, R., Kohrt, H. E., Marabelle, A., Levy, R.
2011; 32 (11): 510-516
 - **SYSTEMIC ANTITUMOR IMMUNITY TRIGGERED BY INTRATUMORAL IMMUNOMODULATION CURES DISTANT METASTATIC CNS LYMPHOMA** *16th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO)/AANS/CNS Section on Tumors*
Marabelle, A., Kohrt, H., Brody, J., Luong, R., Tse, V., Levy, R.
OXFORD UNIV PRESS INC.2011: 38-38
 - **Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.** *International journal of molecular epidemiology and genetics*
Morton, L. M., Cerhan, J. R., Hartge, P., Vasef, M. A., Neppalli, V. T., Natkunam, Y., Dogan, A., Dave, B. J., Jain, S., Levy, R., Lossos, I. S., Cozen, W., Davis, et al
2011; 2 (3): 245-252
 - **Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment** *BLOOD*
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R. H., Gascoyne, R. D., Briones, J., Tibshirani, et al

2011; 118 (5): 1350-1358

● **Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma** *AMERICAN JOURNAL OF HEMATOLOGY*

Ai, W. Z., Kohrt, H. E., Timmerman, J., Hwang, J., Hsu, F. J., Czerwinski, D. D., Taidi, B., Levy, R.
2011; 86 (6): 515-518

● **IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS** *11th International Conference on Malignant Lymphoma*

Brody, J., Advani, R., Czerwinski, D., Negrin, R., Levy, R.
OXFORD UNIV PRESS.2011: 102–102

● **Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results** *JOURNAL OF CLINICAL ONCOLOGY*

Brody, J., Kohrt, H., Marabelle, A., Levy, R.
2011; 29 (14): 1864-1875

● **The Efficacy of HGAL and LMO2 in the Separation of Lymphomas Derived From Small B Cells in Nodal and Extranodal Sites, Including the Bone Marrow** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*

Younes, S. F., Beck, A. H., Ohgami, R. S., Lossos, I. S., Levy, R., Warnke, R. A., Natkunam, Y.
2011; 135 (5): 697-708

● **Immunomodulating antibodies and drugs for the treatment of hematological malignancies** *CANCER AND METASTASIS REVIEWS*

Houot, R., Kohrt, H., Goldstein, M. J., Levy, R.
2011; 30 (1): 97-109

● **CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies** *BLOOD*

Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Mueller, A., Pachynski, R., Czerwinski, D., Coutre, S., Chao, M. P., Chen, L., Tedder, et al
2011; 117 (8): 2423-2432

● **A CpG-loaded tumor cell vaccine induces antitumor CD4(+) T cells that are effective in adoptive therapy for large and established tumors** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*

Goldstein, M. J., Varghese, B., Brody, J. D., Rajapaksa, R., Kohrt, H., Czerwinski, D. K., Levy, S., Levy, R.
AMER SOC HEMATOLOGY.2011: 118–27

● **Escherichia coli-based production of a tumor idiotype antibody fragment - tetanus toxin fragment C fusion protein vaccine for B cell lymphoma** *PROTEIN EXPRESSION AND PURIFICATION*

Patel, K. G., Ng, P. P., Levy, S., Levy, R., Swartz, J. R.
2011; 75 (1): 15-20

● **Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*

Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R., Gascoyne, R. D., Briones, J., Tibshirani, R. J., Myklebust, et al
AMER SOC HEMATOLOGY.2010: 836–37

● **Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*

Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., Advani, R., Natkunam, Y., Levy, R.
AMER SOC HEMATOLOGY.2010: 1291–92

● **CD137 Identifies a Population of Regulatory T Cells That Inhibit Anti-Tumor Immune Responses In Adoptive Immunotherapy** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*

Goldstein, M. J., Kohrt, H. E., Houot, R., Varghese, B., Lin, J. T., Swanson, E., Levy, R.
AMER SOC HEMATOLOGY.2010: 868–68

● **Clinical Translation of a Prognostic Follicular Lymphoma Signaling Profile** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*

Irish, J. M., Czerwinski, D. K., Nolan, G. P., Levy, R.
AMER SOC HEMATOLOGY.2010: 279–79

- **NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Myklebust, J. H., Irish, J. M., Brody, J., Alizadeh, A. A., Czerwinski, D., Houot, R., Kohrt, H. E., Kolstad, A., Levy, R.
AMER SOC HEMATOLOGY.2010: 67–68
- **In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study** *JOURNAL OF CLINICAL ONCOLOGY*
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., Wapnir, I., Tibshirani, R. J., Levy, et al
2010; 28 (28): 4324-4332
- **Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma** *CELL*
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., Park, C. Y., Zhao, F., Kohrt, et al
2010; 142 (5): 699-713
- **Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular and Diffuse Components** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*
Younes, S. F., Beck, A. H., Lossos, I. S., Levy, R., Warnke, R. A., Natkunam, Y.
2010; 34 (9): 1266-1276
- **Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Durnick, D. K., Law, M. E., Maurer, M. J., Natkunam, Y., Levy, R., Lossos, I. S., Kurtin, P. J., McPhail, E. D.
2010; 134 (2): 278-281
- **B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Irish, J. M., Myklebust, J. H., Alizadeh, A. A., Houot, R., Sharman, J. P., Czerwinski, D. K., Nolan, G. P., Levy, R.
2010; 107 (29): 12747-12754
- **Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia** *BLOOD*
Friedberg, J. W., Sharman, J., Sweetenham, J., Johnston, P. B., Vose, J. M., LaCasce, A., Schaefer-Cutillo, J., de Vos, S., Sinha, R., Leonard, J. P., Cripe, L. D., Gregory, S. A., Sterba, et al
2010; 115 (13): 2578-2585
- **C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Anderson, M. W., Zhao, S., Ai, W. Z., Tibshirani, R., Levy, R., Lossos, I. S., Natkunam, Y.
2010; 133 (3): 473-483
- **CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas** *HUMAN PATHOLOGY*
Luo, R. F., Zhao, S., Tibshirani, R., Myklebust, J. H., Sanyal, M., Fernandez, R., Gratzinger, D., Marinelli, R. J., Lu, Z. S., Wong, A., Levy, R., Levy, S., Natkunam, et al
2010; 41 (2): 271-280
- **Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular Component** *99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Younes, S. F., Beck, A., Warnke, R. A., Lossos, I. S., Levy, R., Natkunam, Y.
NATURE PUBLISHING GROUP.2010: 330A–330A
- **Cell-free production of Gaussia princeps luciferase - antibody fragment bioconjugates for ex vivo detection of tumor cells** *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*
Patel, K. G., Ng, P. P., Kuo, C., Levy, S., Levy, R., Swartz, J. R.
2009; 390 (3): 971-976
- **Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., Shyam, R., Natkunam, Y., Gascoyne, R. D., Briones, J., Advani, R., Lossos, I. S., Levy, et al
AMER SOC HEMATOLOGY.2009: 258-58
- **Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*

- Chao, M. P., Alizadeh, A. A., Tang, C. Z., Myklebust, J. H., Varghese, B., Jan, M., Levy, R., Weissman, I. L., Majeti, R.
AMER SOC HEMATOLOGY.2009: 1063–64
- **Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Ng, P. P., Jia, M., Virrueta, A., Patel, K., Swartz, J. R., Levy, S., Levy, R.
AMER SOC HEMATOLOGY.2009: 1062–62
 - **Adoptive Cell Therapy for Lymphoma: Use of CpG-Loaded Tumor Cells to Generate Potent Anti-Tumor CD4 T Cell Immunity** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Gold-Stein, M. J., Varghese, B., Rajapaksa, R., Brody, J., Levy, S., Levy, R.
AMER SOC HEMATOLOGY.2009: 383–83
 - **Therapeutic Potential of Anti-CD137 Antibody in Lymphoma** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., Levy, R.
AMER SOC HEMATOLOGY.2009: 301–2
 - **Adoptive Therapy for Lymphoma with CD4 Memory T Cells Depleted of CD137-Expressing Tregs.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Goldstein, M. J., Houot, R., Kohrt, H. E., Brody, J., Levy, R.
AMER SOC HEMATOLOGY.2009: 674–75
 - **A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Myklebust, J. H., Irish, J. M., Houot, R., Brody, J., Czerwinski, D. K., Alizadeh, A. A., Kolstad, A., Levy, R.
AMER SOC HEMATOLOGY.2009: 316–16
 - **Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., Gentles, A. J., Plevritis, S. K., Levy, R.
AMER SOC HEMATOLOGY.2009: 1153–53
 - **Generation of CD8(+) T cell-mediated immunity against idiotype-negative lymphoma escapees** *BLOOD*
Varghese, B., Widman, A., Do, J., Taidi, B., Czerwinski, D. K., Timmerman, J., Levy, S., Levy, R.
2009; 114 (20): 4477-4485
 - **Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion** *BLOOD*
Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., Levy, R.
2009; 114 (16): 3431-3438
 - **Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant** *IMMUNOTHERAPY*
Brody, J., Levy, R.
2009; 1 (5): 809-824
 - **Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Alizadeh, A. A., Gentles, A. J., Lossos, I. S., Levy, R.
2009; 360 (26): 2794-2795
 - **Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma** *BLOOD*
Ai, W. Z., Tibshirani, R., Taidi, B., Czerwinski, D., Levy, R.
2009; 113 (23): 5743-5746
 - **Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP)** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., Levy, R., Lossos, I. S., Gascoyne, R. D., Natkunam, Y.
AMER SOC CLINICAL ONCOLOGY.2009
 - **Vaccines for lymphomas: Idiotype vaccines and beyond** *BLOOD REVIEWS*
Houot, R., Levy, R.
2009; 23 (3): 137-142
 - **A stem cell-like signature predicts histological transformation and influences survival in follicular lymphoma patients**

- Gentles, A., Alizadeh, A., Lee, S., Shahbaba, B., Shachaf, C., Levy, R., Koller, D., Plevritis, S.
AMER ASSOC CANCER RESEARCH.2009
- **T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy** *BLOOD*
Houot, R., Levy, R.
2009; 113 (15): 3546-3552
 - **The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms and Selected Other Entities** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Gratzinger, D., Zhao, S., West, R., Rouse, R. V., Vogel, H., Gil, E. C., Levy, R., Lossos, I. S., Natkunam, Y.
2009; 131 (2): 264-278
 - **Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors** *BLOOD*
Brody, J. D., Goldstein, M. J., Czerwinski, D. K., Levy, R.
2009; 113 (1): 85-94
 - **Using Immune Response Data from a Lymphoma Vaccine Clinical Trial to Define Novel Endpoints for an Immunotransplant Trial** *9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies*
Brody, J., Czerwinski, D., Ai, W., Levy, R.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2009: S8-S8
 - **CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas** *98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., Wong, A., Talreg, N., Levy, R., Levy, S., Natkunam, Y.
NATURE PUBLISHING GROUP.2009: 275A-275A
 - **Idiotype vaccination for lymphoma: moving towards optimisation** *LEUKEMIA & LYMPHOMA*
Houot, R., Levy, R.
2009; 50 (1): 1-2
 - **Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab** *LEUKEMIA & LYMPHOMA*
Weng, W., Levy, R.
2009; 50 (5): 723-727
 - **Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells** *INTERNATIONAL JOURNAL OF CANCER*
Ai, W. Z., Hou, L., Zeiser, R., Czerwinski, D., Negrin, R. S., Levy, R.
2009; 124 (1): 239-244
 - **Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma** *LEUKEMIA & LYMPHOMA*
Weng, W., Levy, R.
2009; 50 (9): 1494-1500
 - **Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma** *LEUKEMIA & LYMPHOMA*
Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W., Ingolia, D., Mayo, M., Denney, D. W., Levy, R.
2009; 50 (1): 37-46
 - **Neither CD68+Nor CD163+Macrophages Are Associated with Decreased Survival in Follicular Lymphoma** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Gratzinger, D., Ai, W., Tibshirani, R., Levy, R., Natkunam, Y.
AMER SOC HEMATOLOGY.2008: 1284-84
 - **A CpG-Activated Whole-Cell Vaccine 'Boost' Enhances the Anti-Lymphoma Efficacy of Immunotransplant** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Brody, J., Goldstein, M. J., Levy, R.
AMER SOC HEMATOLOGY.2008: 1241-41
 - **Lymphoma-Expressed VEGF-a,VEGFR-1, VEGFR-2, and Microvessel Density Are Not Predictive of Overall Survival in Follicular Lymphoma.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*

- Gratzinger, D., Zhao, S., Ai, W., Tibshirani, R., Levy, R., Natkunam, Y.
AMER SOC HEMATOLOGY.2008: 1290–90
- **Signaling Diversity in Human Lymphoma B Cells and in Tumor Infiltrating T Cells Correlates with Follicular Lymphoma Patient Clinical Outcomes** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Irish, J. M., Houot, R., Myklebust, J. H., Czerwinski, D. K., Nolan, G. P., Levy, R.
AMER SOC HEMATOLOGY.2008: 146–46
 - **Generation of CD8 T Cell-Mediated Protective Immunity against Tumor Escapees.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Varghese, B., Taidi, B., Widman, A., Do, J., Levy, R.
AMER SOC HEMATOLOGY.2008: 908–
 - **A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma** *CLINICAL CANCER RESEARCH*
Racila, E., Link, B. K., Weng, W., Witzig, T. E., Ansell, S., Maurer, M. J., Huang, J., Dahle, C., Halwani, A., Levy, R., Weiner, G. J.
2008; 14 (20): 6697-6703
 - **Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
McCormick, A. A., Reddy, S., Reinal, S. J., Cameron, T. I., Czerwinski, D. K., Vojdani, F., Hanley, K. M., Garger, S. J., White, E. L., Novak, J., Barrett, J., Holtz, R. B., Tuse, et al
2008; 105 (29): 10131-10136
 - **Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP** *BLOOD*
Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., Briones, J., Advani, R., Connors, J. M., Byrne, G. E., Levy, R., Gascoyne, R. D., Lossos, et al
2008; 111 (12): 5509-5514
 - **T cell modulation combined with intratumoral injections of CPG oligodeoxynucleotides cures large and systemic lymphoma tumors in mice** *10th International Conference on Malignant Lymphoma*
Houot, R., Czerwinski, D. K., Levy, R.
OXFORD UNIV PRESS.2008: 160–160
 - **New immunologic treatments for lymphoma** *10th International Conference on Malignant Lymphoma*
Levy, R., Houot, R., Brody, J., Czerwinski, D.
OXFORD UNIV PRESS.2008: 129–129
 - **Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003**
Tan, D., Rosenberg, S. A., Lavori, P., Sigal, B. M., Levy, R., Hoppe, R. T., Warnke, R., Advani, R., Natkunam, Y., Plevritis, S. K., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2008
 - **The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms with rare exceptions**
Gratzinger, D., Zhao, S., Vogel, H., Gil, E. C., Levy, R., Lossos, I., Natkunam, Y.
FEDERATION AMER SOC EXP BIOL.2008
 - **Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis** *BRITISH JOURNAL OF HAEMATOLOGY*
Baecklund, E., Natkunam, Y., Backlin, C., Iliadou, A., Askling, J., Ekbom, A., Feltelius, N., Klareskog, L., Enblad, G., Lossos, I. S., Levy, R., Sundstroem, C., Rosenquist, et al
2008; 141 (1): 69-72
 - **LMO2 protein expression predicts survival in patients with diffuse large B-Cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab** *JOURNAL OF CLINICAL ONCOLOGY*
Natkunam, Y., Farinha, P., Hsi, E. D., Hans, C. P., Tibshirani, R., Sehn, L. H., Connors, J. M., Gratzinger, D., Rosado, M., Zhao, S., Pohlman, B., Wongchaowart, N., Bast, et al
2008; 26 (3): 447-454
 - **LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with or without rituximab** *97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Natkunam, Y., Farinha, P., Hsi, E. D., Hans, C. P., Tibshirani, R., Sehn, L. H., Connors, J. M., Gratzinger, D., Zhan, S., Pohlman, B., Nagler, A., Levy, R., Gascoyne, et al

NATURE PUBLISHING GROUP.2008: 267A–267A

- **Major histocompatibility class II (MHCII) and germinal center associated gene expression correlate with overall survival in rituximab and CHOP-like treated diffuse large B-cell lymphoma (DLBCL) patients, using 49th Annual Meeting of the American-Society-of-Hematology**
Malumbres, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., Tibshirani, R., Briones, J., Connors, J. M., Levy, R., Gascoyne, R. D., Lossos, I. S.
AMER SOC HEMATOLOGY.2007: 23A–23A
- **Survival in follicular lymphoma: The Stanford experience, 1960-2003.** *49th Annual Meeting of the American-Society-of-Hematology*
Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R., Hoppe, R. T., Warnke, R., Advani, R., Natkunam, Y., Yuen, A., Horning, S. J.
AMER SOC HEMATOLOGY.2007: 1005A–1005A
- **Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma** *49th Annual Meeting of the American-Society-of-Hematology*
Ai, W. Z., Tibshirani, R., Taidi, B., Czerwinski, D., Levy, R.
AMER SOC HEMATOLOGY.2007: 199A–199A
- **LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma in, the pre- and post-rituximab treatment eras** *49th Annual Meeting of the American-Society-of-Hematology*
Natkunam, Y., Farinha, P., Hsi, E. D., Hans, C. P., Tibshirani, R., Sehn, L. H., Connors, J. M., Zhao, S., Pohlman, B., Spinelli, J., Bast, M., Nagler, A., Levy, et al
AMER SOC HEMATOLOGY.2007: 24A–24A
- **"Minor" BCL2 breakpoints in follicular lymphoma - Frequency and correlation with grade and disease presentation in 236 cases** *JOURNAL OF MOLECULAR DIAGNOSTICS*
Weinberg, O. K., Ai, W. Z., Mariappan, M. R., Shum, C., Levy, R., Arber, D. A.
2007; 9 (4): 530-537
- **Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself** *JOURNAL OF IMMUNOLOGY*
Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., Krieg, A. M., Levy, R.
2007; 179 (4): 2493-2500
- **Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand** *CANCER RESEARCH*
Liu, A., Guardino, A., Chinsangararn, L., Goldstein, M. J., Panicali, D., Levy, R.
2007; 67 (14): 7037-7044
- **Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines** *BLOOD*
Kanter, G., Yang, J., Voloshin, A., Levy, S., Swartz, J. R., Levy, R.
2007; 109 (8): 3393-3399
- **The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas** *BLOOD*
Natkunam, Y., Zhao, S., Mason, D. Y., Chen, J., Taidi, B., Jones, M., Hammer, A. S., Dutoit, S. H., Lossos, I. S., Levy, R.
2007; 109 (4): 1636-1642
- **Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Natkunam, Y., Vainer, G., Chen, J., Zhao, S., Marinelli, R. J., Hammer, A. S., Hamilton-Dutoit, S., Pikarsky, E., Amir, G., Levy, R., Yisraeli, J. K., Lossos, I. S.
2007; 92 (2): 176-183
- **Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy** *BLOOD*
Weng, W., Czerwinski, D., Levy, R.
2007; 109 (3): 951-953
- **Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival** *BLOOD*
Natkunam, Y., Hsi, E. D., Aoun, P., Zhao, S., Elson, P., Pohlman, B., Naushad, H., Bast, M., Levy, R., Lossos, I. S.
2007; 109 (1): 298-305
- **The oncoprotein LMO2 is expressed in a germinal center B-cell-associated pattern and predicts survival in patients with diffuse large B-cell lymphoma.** *48th Annual Meeting of the American-Society-of-Hematology*
Natkunam, Y., Hsi, E. D., Hans, C., Zhao, S., Taidi, B., Chen, J., Mason, D. Y., Marafioti, T., Jones, M., Pohlman, B., Hammer, A. S., Hamilton-Dutoit, S., Avigdor, et al
AMER SOC HEMATOLOGY.2006: 243A–243A

- **Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells** *BLOOD*
Irish, J. M., Czerwinski, D. K., Nolan, G. P., Levy, R.
2006; 108 (9): 3135-3142
- **Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry** *JOURNAL OF IMMUNOLOGY*
Irish, J. M., Czerwinski, D. K., Nolan, G. P., Levy, R.
2006; 177 (3): 1581-1589
- **Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses** *JOURNAL OF CLINICAL ONCOLOGY*
Redfern, C. H., Guthrie, T. H., Bessudo, A., Densmore, J. J., Holman, P. R., Janakiraman, N., Leonard, J. P., Levy, R. L., Just, R. G., Smith, M. R., Rosenfelt, F. P., Wiernik, P. H., Carter, et al
2006; 24 (19): 3107-3112
- **Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma** *CYTOTHERAPY*
Guardino, A. E., Rajapaksa, R., Ong, K. H., Sheehan, K., Levy, R.
2006; 8 (3): 277-289
- **The T-cell oncprotein LMO2 is expressed in normal germinal center B-cells and in germinal center-derived B-cell lymphoma** *95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Natkunam, Y., Levy, R., Zhao, S., Taidi, B., Lossos, I. S.
NATURE PUBLISHING GROUP.2006: 239A-239A
- **RNA-binding protein VICKZ is expressed in a germinal center associated pattern among lymphoma subtypes** *95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Natkunam, Y., Vainer, G., Zhao, S., Amir, G., Pikarsky, E., Hammer, A. S., Hamilton-Dutoit, S., Levy, R., Yisraeli, J., Lossos, I. S.
NATURE PUBLISHING GROUP.2006: 238A-239A
- **Expression of the human germinal center associated lymphoma (HGAL) protein identifies a subset of classical Hodgkin lymphoma of germinal center derivation and improved outcome** *95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Natkunam, Y., Hsi, E. D., Zhao, S., Elson, P., Pohlman, B., Levy, R., Lossos, I. S.
NATURE PUBLISHING GROUP.2006: 239A-239A
- **RNA-binding protein VICKZ is expressed in a germinal center associated pattern among lymphoma subtypes.** *47th Annual Meeting of the American-Society-of-Hematology*
Natkunam, Y., Vainer, G., Zhao, S. C., Amir, G., Pikarsky, E., Hammer, A. S., Hamilton-Dutoit, S., Levy, R., Yisraeli, J. K., Lossos, I. S.
AMER SOC HEMATOLOGY.2005: 542A-542A
- **Expression of the human germinal center associated lymphoma (HGAL) protein identifies a subset of classical Hodgkin lymphoma of germinal center derivation and improved outcome.** *47th Annual Meeting of the American-Society-of-Hematology*
Natkunam, Y., Hsi, E. D., Zhao, S. C., Elson, P., Pohlman, B., Levy, R., Lossos, I. S.
AMER SOC HEMATOLOGY.2005: 11A-12A
- **Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells** *CANCER RESEARCH*
Song, W. R., Levy, R.
2005; 65 (13): 5958-5964
- **Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation** *BLOOD*
Natkunam, Y., Lossos, I. S., Taidi, B., Zhao, S. C., Lu, X. Q., Ding, F. Y., Hammer, A. S., Marafioti, T., Byrne, G. E., Levy, S., Warnke, R. A., Levy, R.
2005; 105 (10): 3979-3986
- **Cell-free synthesis enables patient-specific vaccine production.** *229th National Meeting of the American-Chemical-Society (ACS)*
Swartz, J. R., Levy, R., Kanter, G., Yang, J. H., Voloshin, A.
AMER CHEMICAL SOC.2005: U202-U203
- **Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system** *BIOTECHNOLOGY AND BIOENGINEERING*
Yang, J. H., Kanter, G., Voloshin, A., Michel-Reydellet, N., Velkeen, H., Levy, R., Swartz, J. R.
2005; 89 (5): 503-511
- **Anti-DNA antibody/cationic lipid micelles for plasmid DNA gene delivery** *ASBM6: ADVANCED BIOMATERIALS VI*
Song, C. X., Wang, M. Y., Yang, J., Jin, X., Mei, L., Leng, X. G., Sun, H. F., Levy, R. J.

2005; 288-289: 105-108

● **The radioisotope contributes significantly to the activity of radioimmunotherapy** *CLINICAL CANCER RESEARCH*

Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Zelenetz, A., Wahl, R. L., KROLL, S., Coleman, M., Goris, M., Levy, R., Knox, S. J. 2004; 10 (23): 7792-7798

● **Cancer vaccines: pessimism in check** *NATURE MEDICINE*

Timmerman, J. M., Levy, R.
2004; 10 (12): 1279-1279

● **Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype** *JOURNAL OF CLINICAL ONCOLOGY*

Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J., Levy, R.
2004; 22 (23): 4717-4724

● **The number of CD25+ tumor-infiltrating cells may predict clinical response to rituximab in follicular lymphoma patients.** *46th Annual Meeting of the American-Society-of-Hematology*

Park, C. Y., Bohm, S. P., Levy, R., Warnke, R. A., Natkunam, Y.
AMER SOC HEMATOLOGY.2004: 214A-214A

● **The percentage of tumor-infiltrating T cells is not correlated with overall survival in follicular B-cell lymphomas** *46th Annual Meeting of the American-Society-of-Hematology*

Ai, W. Y., Czerwinski, D. K., Tibshirani, R., Horning, S. J., Levy, R.
AMER SOC HEMATOLOGY.2004: 891A-891A

● **Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B cell derivation.** *46th Annual Meeting of the American-Society-of-Hematology*

Natkunam, Y., Lossos, I. S., Taidi, B., Zhao, S. C., Lu, X. Q., Ding, F. Y., Hammer, A. S., Marafioti, T., Byrne, G. E., Levy, S., Warnke, R. A., Levy, R.
AMER SOC HEMATOLOGY.2004: 624A-624A

● **Expression of active murine granulocyte-macrophage colony-stimulating factor in an Escherichia coli cell-free system** *BIOTECHNOLOGY PROGRESS*

Yang, J. H., Kanter, G., Voloshin, A., Levy, R., Swartz, J. R.
2004; 20 (6): 1689-1696

● **AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity** *LEUKEMIA*

Lossos, I. S., Levy, R., Alizadeh, A. A.
2004; 18 (11): 1775-1779

● **Vaccines in lymphoma.** *Clinical advances in hematology & oncology : H&O*

Levy, R.
2004; 2 (7): 424-?

● **Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes** *NEW ENGLAND JOURNAL OF MEDICINE*

Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechsler, M. A., Tibshirani, R., Botstein, D., Levy, R.
2004; 350 (18): 1828-1837

● **Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system.** *227th National Meeting of the American-Chemical Society*

Yang, J. H., Kanter, G., Voloshin, A., Levy, R., Swartz, J.
AMER CHEMICAL SOC.2004: U137-U137

● **Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system.** *227th National Meeting of the American-Chemical Society*

Yang, J. H., Kanter, G., Voloshin, A., Levy, R., Swartz, J.
AMER CHEMICAL SOC.2004: U135-U135

● **Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas** *BRITISH JOURNAL OF HAEMATOLOGY*

Reddy, S. A., Levy, R.
2004; 124 (5): 626-628

● **TCR vaccines against a murine T cell lymphoma: A primary role for antibodies of the IgG2c class in tumor protection** *JOURNAL OF IMMUNOLOGY*

Lambert, S. L., Okada, C. Y., Levy, R.

2004; 172 (2): 929-936

- **Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*

Weng, W. K., Levy, R.

2003; 21 (21): 3940-3947

- **Multiple BCL6 translocation partners in individual cases of gastric lymphoma - Response** *BLOOD*

Lossos, I. S., Akasaka, T., Levy, R.

2003; 102 (5): 1932-1932

- **BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma** *BLOOD*

Akasaka, T., Lossos, I. S., Levy, R.

2003; 102 (4): 1443-1448

- **Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma** *LEUKEMIA & LYMPHOMA*

Do, B., Lossos, I. S., Thorstenson, Y., Oefner, P. J., Levy, R.

2003; 44 (8): 1317-1323

- **The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene** *LEUKEMIA*

Lossos, I. S., Akasaka, T., Martinez-Climent, J. A., Siebert, R., Levy, R.

2003; 17 (7): 1390-1397

- **Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions** *SEMINARS IN CANCER BIOLOGY*

Lossos, I. S., Levy, R.

2003; 13 (3): 191-202

- **Diffuse large B-cell lymphoma: Insights gained from gene expression profiling** *INTERNATIONAL JOURNAL OF HEMATOLOGY*

Lossos, I. S., Levy, R.

2003; 77 (4): 321-329

- **Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations** *BLOOD*

Martinez-Climent, J. A., Alizadeh, A. A., Segraves, R., Blesa, D., Rubio-Moscardo, F., Albertson, D. G., Garcia-Conde, J., Dyer, M. J., Levy, R., Pinkel, D., Lossos, I. S.

2003; 101 (8): 3109-3117

- **Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*

Briones, J., Timmerman, J. M., Pancalli, D. L., Levy, R.

2003; 95 (7): 548-555

- **Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies** *LEUKEMIA*

Levy, R.

2003; 17 (4): 796-797

- **Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies** *LEUKEMIA*

Lossos, I. S., Czerwinski, D. K., Wechsler, M. A., Levy, R.

2003; 17 (4): 789-795

- **Variation in gene expression patterns in follicular lymphoma and the response to rituximab** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*

Bohen, S. P., Troyanskaya, O. G., Alter, O., Warnke, R., Botstein, D., Brown, P. O., Levy, R.

2003; 100 (4): 1926-1930

- **HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma** *BLOOD*

Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., Levy, R.

2003; 101 (2): 433-440

- **Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma** *CANCER RESEARCH*

- Timmerman, J. M., Singh, G., Hermanson, G., Hobart, P., Czerwinski, D. K., Taidi, B., Rajapaksa, R., Caspar, C. B., van Beckhoven, A., Levy, R. 2002; 62 (20): 5845-5852
- **BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene LEUKEMIA**
Lossos, I. S., Warnke, R., Levy, R. 2002; 16 (9): 1857-1862
 - **Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA**
Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Thorstenson, Y., Oefner, P. J., Brown, P. O., Botstein, D., Levy, R. 2002; 99 (13): 8886-8891
 - **In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma CANCER RESEARCH**
Briones, J., Timmerman, J., Levy, R. 2002; 62 (11): 3195-3199
 - **Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma LEUKEMIA & LYMPHOMA**
Lossos, I. S., Thorstenson, Y. R., Wayne, T. L., Oefner, P. J., Levy, R., Chu, G. 2002; 43 (5): 1079-1085
 - **Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients BLOOD**
Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., van Beckhoven, A., Liles, T. M., Engleman, et al 2002; 99 (5): 1517-1526
 - **Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients BLOOD**
Auffermann-Gretzinger, S., Lossos, I. S., Vayntrub, T. A., Leong, W., GRUMET, F. C., Blume, K. G., Stockerl-Goldstein, K. E., Levy, R., Shizuru, J. A. 2002; 99 (4): 1442-1448
 - **BLyS* and BLyS receptor expression in non-Hodgkin's lymphoma EXPERIMENTAL HEMATOLOGY**
Briones, J., Timmerman, J. M., Hilbert, D. M., Levy, R. 2002; 30 (2): 135-141
 - **Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: Correlation with clinical outcome LEUKEMIA & LYMPHOMA**
Lossos, I. S., Natkunam, Y., Levy, R., Lopez, C. D. 2002; 43 (12): 2309-2317
 - **A polymorphism in the BCL-6 gene is associated with follicle center lymphoma LEUKEMIA & LYMPHOMA**
Lossos, I. S., Jones, C. D., Zehnder, J. L., Levy, R. 2001; 42 (6): 1343-1350
 - **Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res., 60: 2335-2341, 2000. Cancer research**
Lossos, I. S., Jacobs, Y., Cleary, M. L., Levy, R. 2001; 61 (19): 7363-7364
 - **Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma BLOOD**
Weng, W. K., Levy, R. 2001; 98 (5): 1352-1357
 - **Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma BLOOD**
Lossos, I. S., Jones, C. D., Warnke, R., Natkunam, Y., Kaizer, H., Zehnder, J. L., Tibshirani, R., Levy, R. 2001; 98 (4): 945-951
 - **Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas BLOOD**
Timmerman, J. M., Caspar, C. B., Lambert, S. L., Syrnelas, A. D., Levy, R. 2001; 97 (5): 1370-1377

- **T cell antigen receptor vaccines for active therapy of T cell malignancies** *Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma*
Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R.
NEW YORK ACAD SCIENCES.2001: 97–105
- **Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Davis, T. A., Hsu, F. J., Caspar, C. B., van Beckhoven, A., Czerwinski, D. K., Liles, T. M., Taidi, B., Benike, C. J., Engleman, E. G., Levy, R.
2001; 7 (9): 517-522
- **The inference of antigen selection on Ig genes** *JOURNAL OF IMMUNOLOGY*
Lossos, I. S., Tibshirani, R., Narasimhan, B., Levy, R.
2000; 165 (9): 5122-5126
- **A perspective on monoclonal antibody therapy: Where we have been and where we are going** *Symposium on Monoclonal Antibody Therapy for Hematologic Malignancies - Prospects for an Integrated Therapy Approach*
Levy, R.
W B SAUNDERS CO-ELSEVIER INC.2000: 43–46
- **The history of the development of vaccines for the treatment of lymphoma.** *Clinical lymphoma*
Timmerman, J. M., Levy, R.
2000; 1 (2): 129-139
- **Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment** *JOURNAL OF CLINICAL ONCOLOGY*
Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczmar, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., Levy, R.
2000; 18 (17): 3135-3143
- **Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Lossos, I. S., Alizadeh, A. A., Eisen, M. B., Chan, W. C., Brown, P. O., Botstein, D., Staudt, L. M., Levy, R.
2000; 97 (18): 10209-10213
- **Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene** *BLOOD*
Lossos, I. S., Levy, R.
2000; 96 (2): 635-639
- **Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a** *CLINICAL CANCER RESEARCH*
Davis, T. A., Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Williams, M. E., Weiner, G. J., Dowden, S., Levy, R.
2000; 6 (7): 2644-2652
- **Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma** *CANCER RESEARCH*
Wong, C. P., Levy, R.
2000; 60 (10): 2689-2695
- **Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine** *JOURNAL OF IMMUNOLOGY*
Timmerman, J. M., Levy, R.
2000; 164 (9): 4797-4803
- **Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas** *BLOOD*
Lossos, I. S., Okada, C. Y., Tibshirani, R., Warnke, R., Vose, J. M., Greiner, T. C., Levy, R.
2000; 95 (5): 1797-1803
- **Mutation analysis of the 5' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity** *BLOOD*
Lossos, I. S., Levy, R.
2000; 95 (4): 1400-1405
- **Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling** *NATURE*

- Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. G., Sabet, H., Tran, T., Yu, X., Powell, J. I., Yang, L. M., Marti, et al 2000; 403 (6769): 503-511
- **Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Liso, A., Stockerl-Goldstein, K. E., Auffermann-Gretzinger, S., Benike, C. J., Reichardt, V., van Beckhoven, A., Rajapaksa, R., Engleman, E. G., Blume, K. G., Levy, R.
2000; 6 (6): 621-627
 - **Cytokine fusion constructs as DNA vaccines against tumors.** *Methods in molecular medicine*
Maecker, H. T., Syrengelas, A., Levy, R.
2000; 29: 221-239
 - **'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.** *Genome biology*
Hastie, T., Tibshirani, R., Eisen, M. B., Alizadeh, A., Levy, R., Staudt, L., Chan, W. C., Botstein, D., BROWN, P.
2000; 1 (2): RESEARCH0003-?
 - **Karnofsky Lecture: Immunotherapy of lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Levy, R.
1999; 17 (11): 7-12
 - **1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.** *Biochimica et biophysica acta*
Levy, R.
1999; 1424 (2-3): R43-4
 - **Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab** *JOURNAL OF CLINICAL ONCOLOGY*
Davis, T. A., White, C. A., Grillo-Lopez, A. J., Velasquez, W. S., Link, B., Maloney, D. G., Dillman, R. O., Williams, M. E., MOHRBACHER, A., Weaver, R., Dowden, S., Levy, R.
1999; 17 (6): 1851-1857
 - **DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection** *JOURNAL OF IMMUNOLOGY*
Syrengelas, A. D., Levy, R.
1999; 162 (8): 4790-4795
 - **Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study** *BLOOD*
Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., Blume, K. G., Levy, R.
1999; 93 (7): 2411-2419
 - **TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8(+) T cell response** *JOURNAL OF IMMUNOLOGY*
Wong, C. P., Okada, C. Y., Levy, R.
1999; 162 (4): 2251-2258
 - **Dendritic cell vaccines for cancer immunotherapy** *ANNUAL REVIEW OF MEDICINE*
Timmerman, J. M., Levy, R.
1999; 50: 507-529
 - **The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes** *64th Symposia: Signaling and Gene Expression in the Immune System*
Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., Powell, J. I., Yang, L., Marti, G. E., Moore, D. T., Hudson, J. R., Chan, W. C., Greiner, et al COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT. 1999: 71-78
 - **Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone** *BLOOD*
Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T. M., Levy, R.
1998; 92 (4): 1184-1190
 - **Stereotactic radiosurgery of angiographically occult vascular malformations: 14-year experience** *NEUROSURGERY*
Chang, S. D., Levy, R. P., Adler, J. R., Martin, D. P., Krakovitz, P. R., Steinberg, G. K.
1998; 43 (2): 213-220
 - **Pathological changes in surgically resected angiographically occult vascular malformations after radiation** *NEUROSURGERY*

- Gewirtz, R. J., Steinberg, G. K., Crowley, R., Levy, R. P.
1998; 42 (4): 738-742
- **Identification of peptide ligands for the antigen binding receptor expressed on human B-cell lymphomas.** *Methods in molecular biology* (Clifton, N.J.)
Renschler, M. F., Dower, W. J., Levy, R.
1998; 87: 209-234
 - **TCR vaccines for active immunotherapy of T cell malignancies** *JOURNAL OF IMMUNOLOGY*
Okada, C. Y., Wong, C. P., Denney, D. W., Levy, R.
1997; 159 (11): 5516-5527
 - **Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations** *BLOOD*
Caspar, C. B., Levy, S., Levy, R.
1997; 90 (9): 3699-3706
 - **IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Maloney, D. G., GRILLOLOPEZ, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., Levy, R.
1997; 15 (10): 3266-3274
 - **IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma** *BLOOD*
Maloney, D. G., GRILLOLOPEZ, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, et al
1997; 90 (6): 2188-2195
 - **Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.** *Biology of blood and marrow transplantation*
Reichardt, V. L., Okada, C. Y., Stockerl-Goldstein, K. E., Bogen, B., Levy, R.
1997; 3 (3): 157-163
 - **Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial** *BLOOD*
Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., TAIDILASKOWSKI, B., Levy, R.
1997; 89 (9): 3129-3135
 - **A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein and DNA vaccines** *JOURNAL OF IMMUNOLOGY*
Hakim, I., Levy, S., Levy, R.
1996; 157 (12): 5503-5511
 - **DNA immunization induces protective immunity against B-cell lymphoma** *NATURE MEDICINE*
Syrengelas, A. D., Chen, T. T., Levy, R.
1996; 2 (9): 1038-1041
 - **Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma** *BLOOD*
Nelson, E. L., Li, X. B., Hsu, F. J., Kwak, L. W., Levy, R., CLAYBERGER, C., KRENSKY, A. M.
1996; 88 (2): 580-589
 - **Surgical resection of large incompletely treated intracranial arteriovenous malformations following stereotactic radiosurgery** *JOURNAL OF NEUROSURGERY*
Steinberg, G. K., Chang, S. D., Levy, R. P., Marks, M. P., Frankel, K., Marcellus, M.
1996; 84 (6): 920-928
 - **Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma** *CLINICAL CANCER RESEARCH*
Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T. M., GRILLOLOPEZ, A., Chinn, P., Varns, C., Ning, S. C., Fowler, S., Deb, N., Becker, et al
1996; 2 (3): 457-470
 - **Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody** *BLOOD*
Knox, S., Hoppe, R. T., Maloney, D., Gibbs, I., Fowler, S., Marquez, C., Cornbleet, P. J., Levy, R.
1996; 87 (3): 893-899
 - **Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells** *NATURE MEDICINE*
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., Levy, R.
1996; 2 (1): 52-58

- **B-LYMPHOMA CELLS ARE ACTIVATED BY PEPTIDE LIGANDS OF THE ANTIGEN-BINDING RECEPTOR OR BY ANTIIDIOTYPIC ANTIBODY TO INDUCE EXTRACELLULAR ACIDIFICATION** *CANCER RESEARCH*
Renschler, M. F., Wada, H. G., Fok, K. S., Levy, R.
1995; 55 (23): 5642-5647
- **(90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma**
Davis, T. A., Goris, M. L., Trisler, K. D., Negrin, R., Liles, T. M., Fowler, S. F., Deb, N., Becker, M., Marquez, C. M., Ning, S., Levy, R., Knox, S.
AMER SOC HEMATOLOGY.1995: 1080-80
- **PREFERENTIAL USE OF THE VH4 IG GENE FAMILY BY DIFFUSE LARGE-CELL LYMPHOMA** *BLOOD*
Hsu, F. J., Levy, R.
1995; 86 (8): 3072-3082
- **INDUCTION OF AUTOANTIBODY RESPONSES TO GM-CSF BY HYPERIMMUNIZATION WITH AN ID-GM-CSF FUSION PROTEIN** *JOURNAL OF IMMUNOLOGY*
Chen, T. T., Levy, R.
1995; 154 (7): 3105-3117
- **IDIOTYPE-CYTOKINE FUSION PROTEINS AS CANCER VACCINES - RELATIVE EFFICACY OF IL-2, IL-4, AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR** *JOURNAL OF IMMUNOLOGY*
Chen, T. T., Tao, M. H., Levy, R.
1994; 153 (10): 4775-4787
- **PHASE-I CLINICAL-TRIAL USING ESCALATING SINGLE-DOSE INFUSION OF CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY (IDE-C2B8) IN PATIENTS WITH RECURRENT B-CELL LYMPHOMA** *BLOOD*
Maloney, D. G., Liles, T. M., Czerwinski, D. K., WALDICHUK, C., Rosenberg, J., GRILLOLOPEZ, A., Levy, R.
1994; 84 (8): 2457-2466
- **SYNTHETIC PEPTIDE LIGANDS OF THE ANTIGEN-BINDING RECEPTOR INDUCE PROGRAMMED CELL-DEATH IN A HUMAN B-CELL LYMPHOMA** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Renschler, M. F., Bhatt, R. R., Dower, W. J., Levy, R.
1994; 91 (9): 3623-3627
- **LYMPHOMA REGRESSION INDUCED BY MONOCLONAL ANTIIDIOTYPIC ANTIBODIES CORRELATES WITH THEIR ABILITY TO INDUCE IG SIGNAL-TRANSDUCTION AND IS NOT PREVENTED BY TUMOR EXPRESSION OF HIGH-LEVELS OF BCL-2 PROTEIN** *BLOOD*
Vuist, W. M., Levy, R., Maloney, D. G.
1994; 83 (4): 899-906
- **CELL DYN-3000 AND COULTER STKS AUTOMATED DIFFERENTIAL COUNTERS - REPLY** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Cornbleet, P. J., Myrick, D., Levy, R., JUDKINS, S.
1993; 100 (4): 464-465
- **TRANSFORMATION OF MYCOSIS-FUNGOIDES - T-CELL RECEPTOR-BETA GENE ANALYSIS DEMONSTRATES A COMMON CLONAL ORIGIN FOR PLAQUE-TYPE MYCOSIS-FUNGOIDES AND CD30+ LARGE-CELL LYMPHOMA** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Wood, G. S., Bahler, D. W., Hoppe, R. T., Warnke, R. A., Sklar, J. L., Levy, R.
1993; 101 (3): 296-300
- **CLINICAL-TRIALS OF IDIOTYPE-SPECIFIC VACCINE IN B-CELL LYMPHOMAS** *ANNALS OF THE NEW YORK ACADEMY OF SCIENCES*
Hsu, F. J., Kwak, L., Campbell, M., LILES, T., Czerwinski, D., Hart, S., Syrengelas, A., Miller, R., Levy, R.
1993; 690: 385-387
- **IDIOTYPE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FUSION PROTEIN AS A VACCINE FOR B-CELL LYMPHOMA** *NATURE*
Tao, M. H., Levy, R.
1993; 362 (6422): 755-758
- **ENDOVASCULAR TREATMENT OF CEREBRAL ARTERIOVENOUS-MALFORMATIONS FOLLOWING RADIOSURGERY** *AMERICAN JOURNAL OF NEURORADIOLOGY*
Marks, M. P., Lane, B., Steinberg, G. K., FABRIKANT, J. I., Levy, R. P., Frankel, K. A., Phillips, M. H.
1993; 14 (2): 297-303

- **A SUBMICROSCOPIC INTERSTITIAL DELETION OF CHROMOSOME-14 FREQUENTLY OCCURS ADJACENT TO THE T(14 18) TRANSLOCATION BREAKPOINT IN HUMAN FOLLICULAR LYMPHOMA GENES CHROMOSOMES & CANCER**
Zelenetz, A. D., Cleary, M. L., Levy, R.
1993; 6 (3): 140-150
- **EVALUATION OF THE COULTER STKS 5-PART DIFFERENTIAL AMERICAN JOURNAL OF CLINICAL PATHOLOGY**
Cornbleet, P. J., Myrick, D., Levy, R.
1993; 99 (1): 72-81
- **EVALUATION OF THE CELL-DYN 3000 DIFFERENTIAL AMERICAN JOURNAL OF CLINICAL PATHOLOGY**
Cornbleet, P. J., Myrick, D., JUDKINS, S., Levy, R.
1992; 98 (6): 603-614
- **INDUCTION OF IMMUNE-RESPONSES IN PATIENTS WITH B-CELL LYMPHOMA AGAINST THE SURFACE-IMMUNOGLOBULIN IDIOTYPE EXPRESSED BY THEIR TUMORS NEW ENGLAND JOURNAL OF MEDICINE**
Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., MILLER, R. A., Levy, R.
1992; 327 (17): 1209-1215
- **Antigen selection in human lymphomagenesis. Cancer research**
Bahler, D. W., Zelenetz, A. D., Chen, T. T., Levy, R.
1992; 52 (19): 5547s-5551s
- **CLONAL EXPANSION IN FOLLICULAR LYMPHOMA OCCURS SUBSEQUENT TO ANTIGENIC SELECTION JOURNAL OF EXPERIMENTAL MEDICINE**
Zelenetz, A. D., Chen, T. T., Levy, R.
1992; 176 (4): 1137-1148
- **MONOClonal antiidiotype antibody therapy of B-cell lymphoma - the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells BLOOD**
Maloney, D. G., Brown, S., Czerwinski, D. K., Liles, T. M., Hart, S. M., MILLER, R. A., Levy, R.
1992; 80 (6): 1502-1510
- **CLONAL EVOLUTION OF A FOLLICULAR LYMPHOMA - EVIDENCE FOR ANTIGEN SELECTION PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA**
Bahler, D. W., Levy, R.
1992; 89 (15): 6770-6774
- **TUMOR RESISTANCE INDUCED BY SYNGENEIC BONE-MARROW TRANSPLANTATION AND ENHANCED BY INTERLEUKIN-2 - A MODEL FOR THE GRAFT VERSUS LEUKEMIA REACTION CANCER RESEARCH**
Kwak, L. W., Campbell, M. J., Levy, R.
1992; 52 (15): 4117-4120
- **INTERLEUKIN-3 IS A GROWTH-FACTOR FOR HUMAN FOLLICULAR B-CELL LYMPHOMA JOURNAL OF EXPERIMENTAL MEDICINE**
CLAYBERGER, C., LUNAFINEMAN, S., Lee, J. E., Pillai, A., Campbell, M., Levy, R., KRENSKY, A. M.
1992; 175 (2): 371-376
- **USE OF FAMILY SPECIFIC LEADER REGION PRIMERS FOR PCR AMPLIFICATION OF THE HUMAN HEAVY-CHAIN VARIABLE REGION GENE REPERTOIRE MOLECULAR IMMUNOLOGY**
Campbell, M. J., Zelenetz, A. D., Levy, S., Levy, R.
1992; 29 (2): 193-203
- **DIVERSITY OF T-CELL ANTIGEN RECEPTOR VARIABLE GENES USED BY MYCOSIS-FUNGOIDES CELLS AMERICAN JOURNAL OF PATHOLOGY**
Bahler, D. W., Berry, G., Oksenberg, J., Warnke, R. A., Levy, R.
1992; 140 (1): 1-8
- **TRANSFER OF SPECIFIC IMMUNITY TO B-CELL LYMPHOMA WITH SYNGENEIC BONE-MARROW IN MICE - A STRATEGY FOR USING AUTOLOGOUS MARROW AS AN ANTITUMOR THERAPY BLOOD**
Kwak, L. W., Campbell, M. J., Zelenetz, A. D., Levy, R.
1991; 78 (10): 2768-2772

- **IG VH GENE-EXPRESSION AMONG HUMAN FOLLICULAR LYMPHOMAS *BLOOD***
Bahler, D. W., Campbell, M. J., Hart, S., MILLER, R. A., Levy, S., Levy, R.
1991; 78 (6): 1561-1568
- **ENHANCED DETECTION OF THE T(14-18) TRANSLOCATION IN MALIGNANT-LYMPHOMA USING PULSED-FIELD GEL-ELECTROPHORESIS *BLOOD***
Zelenetz, A. D., Chu, G., Galili, N., Bangs, C. D., Horning, S. J., Donlon, T. A., Cleary, M. L., Levy, R.
1991; 78 (6): 1552-1560
- **AN EPITOPE ON THE TRANSFERRIN RECEPTOR PREFERENTIALLY EXPOSED DURING TUMOR PROGRESSION IN HUMAN LYMPHOMA IS CLOSE TO THE LIGAND-BINDING SITE *BLOOD***
Takahashi, S., Esserman, L., Levy, R.
1991; 77 (4): 826-832
- **AN EXPERIMENTAL COMPARTMENTAL FLOW MODEL FOR ASSESSING THE HEMODYNAMIC-RESPONSE OF INTRACRANIAL ARTERIOVENOUS-MALFORMATIONS TO STEREOTAXIC RADIOSURGERY *NEUROSURGERY***
Lo, E. H., FABRIKANT, J. I., Levy, R. P., Phillips, M. H., Frankel, K. A., ALPEN, E. L.
1991; 28 (2): 251-259
- **FOLLICULAR LYMPHOMA - A MODEL OF LYMPHOID TUMOR PROGRESSION IN MAN *4TH INTERNATIONAL CONF ON MALIGNANT LYMPHOMA***
Zelenetz, A. D., Campbell, M. J., Bahler, D. W., Takahashi, S., Oren, R., Esserman, L., Umetsu, D. T., Kwak, L. W., Maloney, D. G., Brown, S., Chen, T. T., Andria, M. L., Levy, et al
KLUWER ACADEMIC PUBL. 1991: 115-122
- **IDIOTYPE VACCINATION POST-BONE MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA - INITIAL STUDIES IN A MURINE MODEL *CANCER DETECTION AND PREVENTION***
Kwak, L. W., Campbell, M., Levy, R.
1991; 15 (4): 323-325
- **OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES *BLOOD***
Knox, S. J., Levy, R., Hodgkinson, S., Bell, R., Brown, S., Wood, G. S., Hoppe, R., Abel, E. A., Steinman, L., Berger, R. G., Gaiser, C., Young, G., Bindl, et al
1991; 77 (1): 20-30
- **HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LYMPHOMA REPRESENTS TUMOR PROGRESSION BY A SINGLE MALIGNANT B-CELL *JOURNAL OF EXPERIMENTAL MEDICINE***
Zelenetz, A. D., Chen, T. T., Levy, R.
1991; 173 (1): 197-207
- **COMBINED SYNGENEIC BONE-MARROW TRANSPLANTATION AND IMMUNOTHERAPY OF A MURINE B-CELL LYMPHOMA - ACTIVE IMMUNIZATION WITH TUMOR-DERIVED IDIOTYPIC IMMUNOGLOBULIN *BLOOD***
Kwak, L. W., Campbell, M. J., Zelenetz, A. D., Levy, R.
1990; 76 (11): 2411-2417
- **TAPA-1, THE TARGET OF AN ANTIPIROLIFERATIVE ANTIBODY, IS ASSOCIATED ON THE CELL-SURFACE WITH THE LEU-13 ANTIGEN *JOURNAL OF IMMUNOLOGY***
Takahashi, S., Doss, C., Levy, S., Levy, R.
1990; 145 (7): 2207-2213
- **DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES *CANCER RESEARCH***
Knox, S. J., Levy, R., MILLER, R. A., UHLAND, W., Schiele, J., RUEHL, W., FINSTON, R., DAYLOLLINI, P., Goris, M. L.
1990; 50 (16): 4935-4940
- **TAPA-1, THE TARGET OF AN ANTIPIROLIFERATIVE ANTIBODY, DEFINES A NEW FAMILY OF TRANSMEMBRANE PROTEINS *MOLECULAR AND CELLULAR BIOLOGY***
Oren, R., Takahashi, S., Doss, C., Levy, R., Levy, S.
1990; 10 (8): 4007-4015
- **IDIOTYPE VACCINATION AGAINST MURINE B-CELL LYMPHOMA - HUMORAL AND CELLULAR-REQUIREMENTS FOR THE FULL EXPRESSION OF ANTITUMOR IMMUNITY *JOURNAL OF IMMUNOLOGY***

- Campbell, M. J., Esserman, L., BYARS, N. E., Allison, A. C., Levy, R.
1990; 145 (3): 1029-1036
- **STEREOTAXIC HEAVY-CHARGED-PARTICLE BRAGG-PEAK RADIATION FOR INTRACRANIAL ARTERIOVENOUS-MALFORMATIONS** *NEW ENGLAND JOURNAL OF MEDICINE*
Steinberg, G. K., FABRIKANT, J. I., Marks, M. P., Levy, R. P., Frankel, K. A., Phillips, M. H., Shuer, L. M., Silverberg, G. D.
1990; 323 (2): 96-101
- **DIRECTIONAL CLONING OF cDNA USING A SELECTABLE SFII CASSETTE GENE**
Zelenetz, A. D., Levy, R.
1990; 89 (1): 123-127
- **INDUCTION OF PROLIFERATION OF HUMAN FOLLICULAR (B-TYPE) LYMPHOMA-CELLS BY COGNATE INTERACTION WITH CD4+ T-CELL CLONES** *JOURNAL OF IMMUNOLOGY*
Umetsu, D. T., Esserman, L., Donlon, T. A., DeKruyff, R. H., Levy, R.
1990; 144 (7): 2550-2557
- **IDIOTYPIC VARIATION IN A HUMAN B-LYMPHOMA CELL-LINE** *JOURNAL OF IMMUNOLOGY*
Berinstein, N., Campbell, M. J., Lam, K., CARSWELL, C., Levy, S., Levy, R.
1990; 144 (2): 752-758
- **Therapy of lymphoma directed at idiotypes.** *Journal of the National Cancer Institute. Monographs*
Levy, R., MILLER, R. A.
1990: 61-68
- **AN EPITOPE OF THE TRANSFERRIN RECEPTOR IS EXPOSED ON THE CELL-SURFACE OF HIGH-GRADE BUT NOT LOW-GRADE HUMAN LYMPHOMAS BLOOD**
Esserman, L., Takahashi, S., Rojas, V., Warnke, R., Levy, R.
1989; 74 (8): 2718-2729
- **DNA FRAGMENTATION AND CELL-DEATH MEDIATED BY T-CELL ANTIGEN RECEPTOR CD3 COMPLEX ON A LEUKEMIA T-CELL LINE** *EUROPEAN JOURNAL OF IMMUNOLOGY*
Takahashi, S., Maecker, H. T., Levy, R.
1989; 19 (10): 1911-1919
- **FUNCTIONAL IMMUNOGLOBULIN LIGHT CHAIN GENES ARE REPLACED BY ONGOING REARRANGEMENTS OF GERMLINE VK GENES TO DOWNSTREAM JK SEGMENTS IN A MURINE B-CELL LINE** *JOURNAL OF EXPERIMENTAL MEDICINE*
Levy, S., Campbell, M. J., Levy, R.
1989; 170 (1): 1-13
- **ANTIIDIOTYPE ANTIBODY THERAPY OF B-CELL LYMPHOMA** *SEMINARS IN ONCOLOGY*
Brown, S. L., MILLER, R. A., Levy, R.
1989; 16 (3): 199-210
- **CYTOTOXIC LYMPHOCYTE-T SPECIFIC FOR SELF TUMOR IMMUNOGLOBULIN EXPRESS T-CELL RECEPTOR DELTA-CHAIN** *JOURNAL OF EXPERIMENTAL MEDICINE*
Wright, A., Lee, J. E., Link, M. P., Smith, S. D., Carroll, W., Levy, R., CLAYBERGER, C., KRENSKY, A. M.
1989; 169 (5): 1557-1564
- **ACTIVATION OF AN EXCLUDED IMMUNOGLOBULIN ALLELE IN A HUMAN B-LYMPHOMA CELL-LINE** *SCIENCE*
Berinstein, N., Levy, S., Levy, R.
1989; 244 (4902): 337-339
- **TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-IDIOTYPE ANTIBODIES ALONE AND IN COMBINATION WITH ALPHA INTERFERON** *BLOOD*
Brown, S. L., MILLER, R. A., Horning, S. J., Czerwinski, D., Hart, S. M., MCELDERRY, R., BASHAM, T., Warnke, R. A., Merigan, T. C., Levy, R.
1989; 73 (3): 651-661
- **PREVALENCE OF ANTIGEN RECEPTOR VARIANTS IN HUMAN T-CELL LINES AND TUMORS** *JOURNAL OF IMMUNOLOGY*
Maecker, H. T., Levy, R.
1989; 142 (4): 1395-1404

- **Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.** *International reviews of immunology*
Campbell, M. J., Esserman, L., BYARS, N. E., Allison, A. C., Levy, R.
1989; 4 (4): 251-270
- **IMMUNOTHERAPY OF ESTABLISHED MURINE B-CELL LYMPHOMA - COMBINATION OF IDIOTYPE IMMUNIZATION AND CYCLOPHOSPHAMIDE** *JOURNAL OF IMMUNOLOGY*
Campbell, M. J., Esserman, L., Levy, R.
1988; 141 (9): 3227-3233
- **ALTERNATIVE V-KAPPA GENE REARRANGEMENTS IN A MURINE B-CELL LYMPHOMA - AN EXPLANATION FOR IDIOTYPIC HETEROGENEITY** *JOURNAL OF EXPERIMENTAL MEDICINE*
Carroll, W. L., Starnes, C. O., Levy, R., Levy, S.
1988; 168 (5): 1607-1620
- **SPONTANEOUS T-CELL ANTIGEN RECEPTOR VARIANTS OF A HUMAN T-LEUKEMIA CELL-LINE** *JOURNAL OF IMMUNOLOGY*
Maecker, H. T., Levy, R.
1988; 141 (9): 2994-3002
- **SYNERGISTIC ANTITUMOR-ACTIVITY WITH IFN AND MONOCLONAL ANTI-IDIOTYPE FOR MURINE B-CELL LYMPHOMA - MECHANISM OF ACTION** *JOURNAL OF IMMUNOLOGY*
BASHAM, T. Y., RACE, E. R., Campbell, M. J., Reid, T. R., Levy, R., Merigan, T. C.
1988; 141 (8): 2855-2860
- **MUTATIONAL HOT SPOTS IN IG V-REGION GENES OF HUMAN FOLLICULAR LYMPHOMAS** *JOURNAL OF EXPERIMENTAL MEDICINE*
Levy, S., Mendel, E., Kon, S., Avnur, Z., Levy, R.
1988; 168 (2): 475-489
- **COMPARISON OF COMBINATIONS OF INTERFERONS WITH TUMOR SPECIFIC AND NONSPECIFIC MONOCLONAL-ANTIBODIES AS THERAPY FOR MURINE B-CELL AND T-CELL LYMPHOMAS** *CANCER RESEARCH*
BASHAM, T. Y., Palladino, M. A., BADGER, C. C., Bernstein, I. D., Levy, R., Merigan, T. C.
1988; 48 (15): 4196-4200
- **HETEROGENEITY OF A MURINE B-CELL LYMPHOMA - ISOLATION AND CHARACTERIZATION OF IDIOTYPIC VARIANTS** *JOURNAL OF IMMUNOLOGY*
Starnes, C. O., Carroll, W. L., Campbell, M. J., Houston, L. L., Apell, G., Levy, R.
1988; 141 (1): 333-339
- **SPECIFIC ENHANCEMENT OF THE THERAPEUTIC EFFECT OF ANTI-IDIOTYPE ANTIBODIES ON A MURINE B-CELL LYMPHOMA BY IL-2** *JOURNAL OF IMMUNOLOGY*
Berinstein, N., Starnes, C. O., Levy, R.
1988; 140 (8): 2839-2845
- **IDIOTYPE AS A TUMOR-SPECIFIC MARKER IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA** *BLOOD*
Carroll, W. L., Link, M. P., Cleary, M. L., Bologna, S., CARSWELL, C., Amylon, M. D., Smith, S. D., Levy, R.
1988; 71 (4): 1068-1073
- **SINGLE CELL ORIGIN OF BIGENOTYPIC AND BIPHENOTYPIC B-CELL PROLIFERATIONS IN HUMAN FOLLICULAR LYMPHOMAS** *JOURNAL OF EXPERIMENTAL MEDICINE*
Cleary, M. L., Galili, N., Trela, M., Levy, R., Sklar, J.
1988; 167 (2): 582-597
- **ANTIBODY-DIRECTED TARGETING OF LIPOSOMES TO HUMAN CELL-LINES - ROLE OF BINDING AND INTERNALIZATION ON GROWTH-INHIBITION** *CANCER RESEARCH*
Berinstein, N., Matthay, K. K., Papahadjopoulos, D., Levy, R., Sikic, B. I.
1987; 47 (22): 5954-5959
- **IDIOTYPE VACCINATION AGAINST MURINE B-CELL LYMPHOMA - HUMORAL AND CELLULAR-RESPONSES ELICITED BY TUMOR-DERIVED IMMUNOGLOBULIN-M AND ITS MOLECULAR SUBUNITS** *JOURNAL OF IMMUNOLOGY*
Campbell, M. J., Carroll, W., Kon, S., Thielemans, K., Rothbard, J. B., Levy, S., Levy, R.
1987; 139 (8): 2825-2833

- **TREATMENT OF A MURINE B-CELL LYMPHOMA WITH MONOCLONAL-ANTIBODIES AND IL-2** *JOURNAL OF IMMUNOLOGY*
Berinstein, N., Levy, R.
1987; 139 (3): 971-976
- **ISOLATION OF ANTIIDIOTYPIC ANTIBODIES TO T-CELLS USING AN ANTI-FRAMEWORK DETERMINANT ANTIBODY** *JOURNAL OF IMMUNOLOGICAL METHODS*
Maecker, H. T., Kitamura, K., Brenner, M. B., Levy, R.
1987; 98 (2): 219-226
- **INVITRO TESTS THAT PREDICT TUMOR-ASSOCIATED IDIOTYPE LEVELS IN THE SERUM OF PATIENTS WITH B-CELL LYMPHOMAS AND LEUKEMIAS** *BLOOD*
MILLER, R. A., Lowder, J. N., Gralow, J., Meeker, T., Levy, R.
1987; 69 (4): 1249-1254
- **ANTI-IDIOTYPE ANTIBODIES REVEAL THE EXISTENCE OF SOMATIC MUTATION IN HUMAN B-CELL LYMPHOMA** *MONOGRAPH IN ALLERGY*
Levy, R., Levy, S., Brown, S. L., Kon, S., Carroll, W.
1987; 22: 194-203
- **STUDIES ON B-LYMPHOID TUMORS TREATED WITH MONOCLONAL ANTIIDIOTYPE ANTIBODIES - CORRELATION WITH CLINICAL-RESPONSES** *BLOOD*
Lowder, J. N., MEEKER, T. C., Campbell, M., Garcia, C. F., Gralow, J., MILLER, R. A., Warnke, R., Levy, R.
1987; 69 (1): 199-210
- **SYNERGISTIC ANTITUMOR EFFECT OF INTERFERON AND ANTIIDIOTYPE MONOCLONAL-ANTIBODY IN MURINE LYMPHOMA** *JOURNAL OF IMMUNOLOGY*
BASHAM, T. Y., Kaminski, M. S., Kitamura, K., Levy, R., Merigan, T. C.
1986; 137 (9): 3019-3024
- **A UNIQUE ANTIGEN ON MATURE B-CELLS DEFINED BY A MONOCLONAL-ANTIBODY** *JOURNAL OF IMMUNOLOGY*
Link, M. P., Bindl, J., MEEKER, T. C., CARSWELL, C., DOSS, C. A., Warnke, R. A., Levy, R.
1986; 137 (9): 3013-3018
- **MOUSE X HUMAN HETEROHYBRIDOMAS AS FUSION PARTNERS WITH HUMAN B-CELL TUMORS** *JOURNAL OF IMMUNOLOGICAL METHODS*
Carroll, W. L., Thielemans, K., Dilley, J., Levy, R.
1986; 89 (1): 61-72
- **CLUSTERING OF EXTENSIVE SOMATIC MUTATIONS IN THE VARIABLE REGION OF AN IMMUNOGLOBULIN HEAVY-CHAIN GENE FROM A HUMAN B-CELL LYMPHOMA** *CELL*
Cleary, M. L., MEEKER, T. C., Levy, S., Lee, E., Trella, M., Sklar, J., Levy, R.
1986; 44 (1): 97-106
- **The immunobiology of B cell lymphoma: clonal heterogeneity as revealed by anti-idiotype antibodies and immunoglobulin gene probes.** *Symposium on Fundamental Cancer Research*
Levy, R., Meeker, T., Lowder, J., Levy, S., Thielemans, K., Warnke, R. A., Cleary, M. L., Sklar, J.
1986; 38: 261-268
- **SYNGENEIC ANTIIDIOTYPIC IMMUNE-RESPONSES TO A B-CELL LYMPHOMA - COMPARISON BETWEEN HEAVY-CHAIN HYPERVARIABLE REGION PEPTIDES AND INTACT IG AS IMMUNOGENS** *JOURNAL OF EXPERIMENTAL MEDICINE*
Thielemans, K., Rothbard, J. B., Levy, S., Levy, R.
1985; 162 (1): 19-34
- **MONOCLONAL-ANTIBODY THERAPY OF LYMPHOID MALIGNANCY** *CANCER SURVEYS*
Lowder, J. N., MEEKER, T. C., Levy, R.
1985; 4 (2): 359-375
- **EMERGENCE OF IDIOTYPE VARIANTS DURING TREATMENT OF B-CELL LYMPHOMA WITH ANTI-IDIOTYPE ANTIBODIES** *NEW ENGLAND JOURNAL OF MEDICINE*
Meeker, T., Lowder, J., Cleary, M. L., Stewart, S., Warnke, R., Sklar, J., Levy, R.
1985; 312 (26): 1658-1665

- **A CLINICAL-TRIAL OF ANTI-IDIOTYPE THERAPY FOR B-CELL MALIGNANCY BLOOD**
MEEKER, T. C., Lowder, J., Maloney, D. G., MILLER, R. A., Thielemans, K., Warnke, R., Levy, R.
1985; 65 (6): 1349-1363
- **DIFFERENCES IN HOST INFILTRATES AMONG LYMPHOMA PATIENTS TREATED WITH ANTI-IDIOTYPE ANTIBODIES - CORRELATION WITH TREATMENT RESPONSE JOURNAL OF IMMUNOLOGY**
Garcia, C. F., Lowder, J., MEEKER, T. C., Bindl, J., Levy, R., Warnke, R. A.
1985; 135 (6): 4252-4260
- **DETECTION OF B-CELL LYMPHOMA IN PERIPHERAL-BLOOD BY DNA HYBRIDIZATION LANCET**
Hu, E., Thompson, J., Horning, S., Trella, M., Lowder, J., Levy, R., Sklar, J.
1985; 2 (8464): 1092-1095
- **BICLONAL B-CELL LYMPHOMA NEW ENGLAND JOURNAL OF MEDICINE**
Sklar, J., Cleary, M. L., Thielemans, K., Gralow, J., Warnke, R., Levy, R.
1984; 311 (1): 20-27
- **CLINICAL RELEVANCE OF IMMUNOLOGICAL PHENOTYPE IN DIFFUSE LARGE CELL LYMPHOMA BLOOD**
Horning, S. J., Doggett, R. S., Warnke, R. A., Dorfman, R. F., Cox, R. S., Levy, R.
1984; 63 (5): 1209-1215
- **PAN-LEUKOCYTE MONOCLONAL ANTIBODY-L3B12 - CHARACTERIZATION AND APPLICATION TO RESEARCH AND DIAGNOSTIC PROBLEMS AMERICAN JOURNAL OF CLINICAL PATHOLOGY**
Wood, G. S., Link, M., Warnke, R. A., Dilley, J., Levy, R.
1984; 81 (2): 176-183
- **THE IMMUNOLOGICAL CHARACTERIZATION OF 95 NODAL AND EXTRANODAL DIFFUSE LARGE CELL LYMPHOMAS IN 89 PATIENTS AMERICAN JOURNAL OF PATHOLOGY**
Doggett, R. S., Wood, G. S., Horning, S., Levy, R., Dorfman, R. F., Bindl, J., Warnke, R. A.
1984; 115 (2): 245-252
- **A UNIQUE HUMAN LYMPHOCYTE-B ANTIGEN DEFINED BY A MONOCLONAL-ANTIBODY HYBRIDOMA**
MEEKER, T. C., MILLER, R. A., Link, M. P., Bindl, J., Warnke, R., Levy, R.
1984; 3 (4): 305-320
- **STRATEGIES FOR PRODUCTION OF MONOCLONAL ANTI-IDIOTYPE ANTIBODIES AGAINST HUMAN B-CELL LYMPHOMAS JOURNAL OF IMMUNOLOGY**
Thielemans, K., Maloney, D. G., Meeker, T., Fujimoto, J., Doss, C., Warnke, R. A., Bindl, J., Gralow, J., MILLER, R. A., Levy, R.
1984; 133 (1): 495-501
- **STANFORD STUDY OF SEZARY SYNDROME JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY**
Rich, L., Levy, R., Horning, S., Merigan, T. C.
1983; 9 (2): 279-279
- **A SINGLE MONOCLONAL-ANTIBODY IDENTIFIES T-CELL LINEAGE OF CHILDHOOD LYMPHOID MALIGNANCIES BLOOD**
Link, M., Warnke, R., Finlay, J., Amylon, M., Miller, R., Dilley, J., Levy, R.
1983; 62 (4): 722-728
- **STUDIES OF A HUMAN LYMPHOCYTE-T ANTIGEN RECOGNIZED BY A MONOCLONAL-ANTIBODY PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES**
Engleman, E. G., Warnke, R., FOX, R. I., Dilley, J., Benike, C. J., Levy, R.
1981; 78 (3): 1791-1795
- **INHIBITION OF LYMPHOMA HYBRIDS BY HUMAN INTERFERON LANCET**
Sikora, K., Dilley, J., Merigan, T., BASHAM, T., Levy, R.
1980; 2 (8200): 891-893
- **HUMAN THYMUS-LEUKEMIA ANTIGEN DEFINED BY HYBRIDOMA MONOCLONAL-ANTIBODIES PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA**
Levy, R., Dilley, J., FOX, R. I., Warnke, R.

1979; 76 (12): 6552-6556

• **EFFECTS OF INTERFERON ON PATIENTS WITH NON-HODGKINS LYMPHOMA**

Sikora, K., Levy, R., Merigan, T., Rosenberg, S.
AMER ASSOC CANCER RESEARCH.1979: 299-99

• **PRELIMINARY-OBSERVATIONS ON EFFECT OF HUMAN LEUKOCYTE INTERFERON IN NON-HODGKINS LYMPHOMA NEW ENGLAND JOURNAL OF MEDICINE**

Merigan, T. C., Sikora, K., BREEDEN, J. H., Levy, R., Rosenberg, S. A.
1978; 299 (26): 1449-1453